This website publishes administrative rules on their effective dates, as designated by the adopting state agencies, colleges, and
universities.
| Rule |
Rule 3701:1-58-01 | Definitions.
Effective:
August 15, 2021
The terms used in this chapter have the same
meaning as found in rule 3701:1-38-01 of the Administrative Code, unless an
alternative definition is provided in this rule or in another rules of this
chapter: (A) "Associate radiation safety
officer" means an individual who: (1) Meets the
requirements in rules 3701:1-58-18 and 3701:1-58-22 of the Administrative Code;
and (2) Is currently
identified as an associate radiation safety officer for the types of use of
radioactive material for which the individual has been assigned duties and
tasks by the radiation safety officer on: (a) A specific medical use license issued by the director,
the United States nuclear regulatory commission, or an agreement state;
or (b) A medical use permit issued by a United States nuclear
regulatory commission master material licensee. (B) "Authorized medical
physicist" means an individual who: (1) Meets the
requirements in paragraph (A) of rule 3701:1-58-19 and in rule 3701:1-58-22 of
the Administrative Code; or (2) Is identified as an
authorized medical physicist or teletherapy physicist on: (a) A specific medical use license issued by the director,
the United States nuclear regulatory commission, or an agreement
state; (b) A medical use permit issued by a United States nuclear
regulatory commission master material licensee; (c) A permit issued by a United States nuclear regulatory
commission or agreement state broad scope medical use licensee; or (d) A permit issued by a United States nuclear regulatory
commission master material license broad scope medical use
permittee. (C) "Authorized nuclear pharmacist" means a
pharmacist who: (1) Meets the
requirements in paragraph (A) of rule 3701:1-58-20 and in rule 3701:1-58-22 of
the Administrative Code; or (2) Is identified as an
authorized nuclear pharmacist on: (a) A specific license issued by the director, the United States
nuclear regulatory commission, or an agreement state that authorizes medical
use or the practice of nuclear pharmacy; (b) A permit issued by a United States nuclear regulatory
commission master material licensee that authorizes medical use or the practice
of nuclear pharmacy; (c) A permit issued by a United States nuclear regulatory
commission or agreement state broad scope medical use licensee that authorizes
medical use or the practice of nuclear pharmacy; or (d) A permit issued by a United States nuclear regulatory
commission master material license broad scope medical use permittee that
authorizes medical use or the practice of nuclear pharmacy; or (3) Is identified as an
authorized nuclear pharmacist by a commercial nuclear pharmacy that has been
authorized to identify authorized nuclear pharmacists; or (4) Is designated as an
authorized nuclear pharmacist in accordance with rule 3701:1-46-43 of the
Administrative Code. (D) "Authorized user" means a physician, dentist,
or podiatrist who: (1) Meets the
requirements in rule 3701:1-58-22 of the Administrative Code and paragraph (A)
of rule 3701:1-58-33, paragraph (A) of rule 3701:1-58-36, paragraph (A) of rule
3701:1-58-40, paragraph (A) of rule 3701:1-58-41, paragraph (A) of rule
3701:1-58-42, paragraph (A) of rule 3701:1-58-51, paragraph (A) of rule
3701:1-58-54, or paragraph (A) of rule 3701:1-58-71 of the Administrative Code;
or (2) Is identified as an
authorized user on: (a) A license issued by the director, the United States nuclear
regulatory commission, or an agreement state that authorizes the medical use of
radioactive material; (b) A permit issued by a United States nuclear regulatory
commission master material licensee that is authorized to permit the medical
use of radioactive material; (c) A permit issued by a United States nuclear regulatory
commission or agreement state specific licensee of broad scope that is
authorized to permit the medical use of radioactive material; or (d) A permit issued by a United States nuclear regulatory
commission master material license broad scope permittee that is authorized to
permit the medical use of radioactive material. (E) "Brachytherapy" means a method of radiation
therapy in which sources are used to deliver a radiation dose at a distance of
up to a few centimeters by surface, intracavitary, intraluminal, or
interstitial application. (F) "Brachytherapy source" means a radioactive
source or a manufacturer-assembled source train or a combination of these
sources that is designed to deliver a therapeutic dose within a distance of a
few centimeters. (G) "Client's address" means the area of
use or a temporary job site, as defined in this rule, for the purpose of
providing mobile medical service in accordance with rule 3701:1-58-31 of the
Administrative Code. (H) "High dose-rate remote afterloader," as used
in this chapter, means a brachytherapy device that remotely delivers a dose
rate in excess of twelve gray (one thousand two hundred rads) per hour at the
point or surface where the dose is prescribed. (I) "Low dose-rate remote afterloader," as used
in this chapter, means a brachytherapy device that remotely delivers a dose
rate of less than or equal to two gray (two hundred rads) per hour at the point
or surface where the dose is prescribed. (J) "Manual brachytherapy," as used in this
chapter, means a type of brachytherapy in which the brachytherapy sources, such
as seeds or ribbons are manually placed topically on or inserted either into
the body cavities that are in close proximity to a treatment site or directly
into the tissue volume. (K) "Medical event" means an event that meets the
criteria in paragraph (A) or (B) of rule 3701:1-58-101 of the Administrative
Code. (L) "Medium dose-rate remote afterloader," as
used in this chapter, means a brachytherapy device that remotely delivers a
dose rate of greater than two gray (two hundred rads) per hour, but less than
or equal to twelve gray (one thousand two hundred rads) per hour at the point
or surface where the dose is prescribed. (M) "Mobile medical service" means the
transportation of radioactive material to and its medical use at the
client's address. (N) "Ophthalmic physicist"
means an individual who: (1) Meets the
requirements in paragraph (A)(2) of rule 3701:1-58-49 and in rule 3701:1-58-22
of the Administrative Code; and (2) Is identified as an
ophthalmic physicist on a: (a) Specific medical use license issued by the director,
the United States nuclear regulatory commission, or an agreement
state; (b) Permit issued by a United States nuclear regulatory
commission or agreement state broad scope medical use licensee; (c) Medical use permit issued by a United States nuclear
regulatory commission master material licensee; or (d) Permit issued by a United States nuclear regulatory
commission master material licensee broad scope medical use
permittee. (O) "Output" means the exposure rate, dose rate,
or a quantity related in a known manner to these rates from a brachytherapy
source or a teletherapy, remote afterloader, or gamma stereotactic radiosurgery
unit for a specified set of exposure conditions. (P) "Patient intervention" means actions by the
patient or human research subject, whether intentional or unintentional, such
as dislodging or removing treatment devices or prematurely terminating the
administration. (Q) "Personal Representative" means: (1) A person who has
authority to act on behalf of an individual who is an adult or an emancipated
minor in making decisions related to health care, or (2) A parent, guardian,
or other person acting in loco parentis who has authority to act on behalf of
an individual who is an unemancipated minor in making decisions related to
health care. (R) "Preceptor" means an individual who provides,
directs, or verifies the training and experience required for an individual to
become an authorized user, an authorized medical physicist, an authorized
nuclear pharmacist, a radiation safety officer, or an associate radiation
safety officer. (S) "Prescribed dosage" means the specified
activity or range of activity of unsealed radioactive material as
documented: (1) In a written
directive; or (2) In accordance with
the directions of the authorized user for procedures performed pursuant to
rules 3701:1-58-32 and 3701:1-58-34 of the Administrative Code. (T) "Prescribed dose" means: (1) For gamma
stereotactic radiosurgery, the total dose as documented in the written
directive; (2) For teletherapy, the
total dose and dose per fraction as documented in the written
directive; (3) For manual
brachytherapy, either the total source strength and exposure time or the total
dose, as documented in the written directive; or (4) For remote
brachytherapy afterloaders, the total dose and dose per fraction as documented
in the written directive. (U) "Pulsed dose-rate remote afterloader," as
used in this chapter, means a special type of remote afterloading brachytherapy
device that uses a single source capable of delivering dose rates in the
"high dose-rate'' range, but: (1) Is approximately
one-tenth of the activity of typical high dose-rate remote afterloader sources;
and (2) Is used to simulate
the radiobiology of a low dose-rate treatment by inserting the source for a
given fraction of each hour. (V) "Radiation safety officer," as used in this
chapter, means an individual who: (1) Meets the
requirements in paragraph (A) or (C)(1) of rule 3701:1-58-18 and in rule
3701:1-58-22 of the Administrative Code, or (2) Is identified as a
radiation safety officer on: (a) A specific medical use license issued by the director, the
United States nuclear regulatory commission, or an agreement state that
authorizes the medical use of radioactive material; or (b) A medical use permit issued by a United States nuclear
regulatory commission master material licensee. (W) "Stereotactic radiosurgery" means the use of
external radiation in conjunction with a stereotactic guidance device to very
precisely deliver a therapeutic dose to a tissue volume. (X) "Structured educational program" means an
educational program designed to impart particular knowledge and practical
education through interrelated studies and supervised training. (Y) "Teletherapy," as used in this chapter, means
a method of radiation therapy in which collimated gamma rays are delivered at a
distance from the patient or human research subject. (Z) "Teletherapy Physicist" means the individual
identified as the teletherapy physicist on a radioactive material license
issued by the state of Ohio. (AA) "Temporary job site," as used in this
chapter, means a location where mobile medical services are conducted other
than those location(s) of use authorized on the license. (BB) "Therapeutic dosage" means a dosage of
unsealed radioactive material that is intended to deliver a radiation dose to a
patient or human research subject for palliative or curative
treatment. (CC) "Therapeutic dose" means a radiation dose
delivered from a source containing radioactive material to a patient or human
research subject for palliative or curative treatment. (DD) "Treatment site" means the anatomical
description of the tissue intended to receive a radiation dose, as described in
a written directive. (EE) "Type of use" means use of radioactive
material under rule 3701:1-58-32, 3701:1-58-34, 3701:1-58-37, 3701:1-58-43,
3701:1-58-53, 3701:1-58-55 or 3701:1-58-72 of the Administrative
Code. (FF) "Unit dosage" means a dosage prepared for
medical use for administration as a single dosage to a patient or human
research subject without any further manipulation of the dosage after it is
initially prepared. (GG) "Written directive," as specified in rule
3701:1-58-15 of the Administrative Code, means an authorized user's
written order for the administration of radioactive material or radiation from
radioactive material to a specific patient or human research
subject.
Last updated November 18, 2022 at 8:27 AM
|
Rule 3701:1-58-02 | Purpose and scope.
Effective:
August 15, 2005
This chapter contains the requirements and provisions for the medical use of radioactive material and for issuance of specific licenses authorizing the medical use of this material. These requirements and provisions provide for the radiation safety of workers, the general public, patients, and human research subjects. The requirements and provisions of this chapter are in addition to, and not in substitution for, other rules of the Administrative Code. The requirements and provisions of Chapters 3701:1-38, 3701:1-40, and 3701:1-50 of the Administrative Code also apply to applicants and licensees subject to this chapter unless specifically exempted.
Last updated November 18, 2022 at 8:28 AM
|
Rule 3701:1-58-03 | Maintenance of records.
Effective:
August 15, 2005
Each record required by this chapter must be legible throughout the specified retention period. The record may be the original, a reproduced copy, or a microform if the copy or microform is authenticated by authorized personnel and the microform is capable of producing a clear copy throughout the required retention period. The record may also be stored in electronic media with the capability for producing legible, accurate, and complete records during the required retention period. Records such as letters, drawings, and specifications must include all pertinent information such as stamps, initials, and signatures. The licensee shall maintain adequate safeguards against tampering with and loss of records.
Last updated November 18, 2022 at 8:28 AM
|
Rule 3701:1-58-04 | Provisions for the protection of human research subjects.
Effective:
April 17, 2022
(A) A licensee may conduct research
involving human research subjects only if it uses the radioactive materials
specified on its license for the uses authorized on its license. (B) If the research is conducted, funded,
supported, or regulated by a federal agency that has implemented the federal
policy for the protection of human subjects as specified in 45 C.F.R. Part 46
(as in effect on the effective date of this rule), the licensee shall, before
conducting research: (1) Obtain review and
approval of the research from an "institutional review board," as
defined and described in the federal policy; and (2) Obtain "informed
consent," as defined and described in the federal policy, from the human
research subject. (C) If the research will not be
conducted, funded, supported, or regulated by a federal agency that has
implemented the federal policy, the licensee shall, before conducting research,
apply for and receive a specific amendment to its medical use license. The
amendment request must include a written commitment that the licensee will,
before conducting research: (1) Obtain review and
approval of the research from an "institutional review board," as
defined and described in the federal policy, and approved by the office of
human research protection; and (2) Obtain "informed
consent," as defined and described in the federal policy, from the human
research subject. (D) Nothing in this rule relieves
licensees from complying with the other requirements in this
chapter.
Last updated April 19, 2022 at 8:38 AM
|
Rule 3701:1-58-05 | United States food and drug administration, other federal, and state requirements.
Effective:
August 15, 2005
Nothing in this chapter relieves the licensee from complying with applicable United States food and drug administration, other federal, and state requirements governing radioactive drugs or devices.
Last updated November 18, 2022 at 8:28 AM
|
Rule 3701:1-58-06 | License required.
Effective:
October 4, 2010
(A) A person may manufacture, produce, acquire, receive, possess, prepare, use, or transfer radioactive material for medical use only in accordance with a specific license issued by the director, United States nuclear regulatory commission, an agreement state, or as allowed in paragraph (B)(1) or (B)(2) of this rule. (B) A specific license is not needed for an individual who: (1) Receives, possesses, uses, or transfers radioactive material in accordance with the regulations in this chapter under the supervision of an authorized user as provided in rule 3701:1-58-14 of the Administrative Code, unless prohibited by license condition; or (2) Prepares unsealed radioactive material for medical use in accordance with the regulations in this chapter under the supervision of an authorized nuclear pharmacist or authorized user as provided in rule 3701:1-58-14 of the Administrative Code, unless prohibited by license condition.
Last updated November 18, 2022 at 8:28 AM
|
Rule 3701:1-58-07 | Application for license, amendment or renewal.
Effective:
August 15, 2021
(A) An application must be signed by the applicant's
or licensee's "management," as defined in rule 3701:1-38-01 of
the Administrative Code. (B) An application for a license for medical use of
radioactive material, as described in rules 3701:1-58-32, 3701:1-58-34,
3701:1-58-37, 3701:1-58-43, 3701:1-58-53, 3701:1-58-55, and 3701:1-58-72 of the
Administrative Code, must be made by: (1) Submitting documentation in accordance with rule
3701:1-40-14 of the Administrative Code, and including the facility diagram;
equipment; and training and experience qualifications of the radiation safety
officer, associate radiation safety officer(s), authorized user(s), authorized
medical physicist(s), ophthalmic physicist(s), and authorized nuclear
pharmacist(s); (2) Submitting the appropriate license fees listed in rule
3701:1-38-02 of the Administrative Code after receiving an invoice from the
department; and (3) Submitting procedures required by rules 3701:1-58-58
and 3701:1-58-64 to 3701:1-58-66 of the Administrative Code, as
applicable. (C) A
request for a license amendment or renewal must be made by: (1) Submitting documentation in accordance with rule
3701:1-40-14 of the Administrative Code; (2) Submitting the appropriate license or amendment fees
listed in rule 3701:1-38-02 of the Administrative Code after receiving an
invoice from the department; and (3) Submitting procedures required by rules 3701:1-58-58
and 3701:1-58-64 to 3701:1-58-66 of the Administrative Code, as
applicable. (D) In addition to the requirements in paragraphs (B) and
(C) of this rule, an application for a license or amendment for medical use of
radioactive material as described in rule 3701:1-58-72 of the Administrative
Code must also include: (1) Any additional aspects of the medical use of the
material that are applicable to radiation safety that are not addressed in, or
differ from, rules 3701:1-58-01 to 3701:1-58-31, 3701:1-58-73 to 3701:1-58-103,
and 3701:1-58-105 of the Administrative Code; (2) Identification of and commitment to follow the
applicable radiation safety program requirements in rules 3701:1-58-32 to
3701:1-58-71 and 3701:1-58-104 of the Administrative Code that are appropriate
for the specific rule 3701:1-58-72 of the Administrative Code medical
use; (3) Any additional specific information on: (a) Radiation safety
precautions and instructions; (b) Methodology for
measurement of dosages or doses to be administered to patients or human
research subjects; and (c) Calibration,
maintenance, and repair of instruments and equipment necessary for radiation
safety; and (4) Any other information requested by the director in
review of the application. (E) An applicant that satisfies the requirements specified
in rule 3701:1-40-23 of the Administrative Code may apply for a type A specific
license of broad scope.
Last updated November 18, 2022 at 8:28 AM
|
Rule 3701:1-58-08 | License amendments.
Effective:
August 15, 2021
A licensee shall apply for and must receive a
license amendment and pay the invoiced amendment fee specified in rule
3701:1-38-02 of the Administrative Code: (A) Before it receives, prepares, or uses
radioactive material for a type of use that is permitted under this chapter,
but that is not authorized on the licensee's current license issued under
this chapter, and Chapter 3701:1-40 of the Administrative Code; (B) Before it permits anyone to work as
an authorized user, authorized nuclear pharmacist, ophthalmic physicist, or
authorized medical physicist under the license, except: (1) For an authorized
user, an individual who meets the requirements in rule 3701:1-58-22, and
paragraph (A) of rule 3701:1-58-33, paragraph (A) of rule 3701:1-58-36,
paragraph (A) of rule 3701:1-58-40, paragraph (A) of rule 3701:1-58-41,
paragraph (A) of rule 3701:1-58-42, paragraph (A) of rule 3701:1-58-51,
paragraph (A) of rule 3701:1-58-54, and paragraph (A) of rule 3701:1-58-71 of
the Administrative Code. (2) For an authorized
nuclear pharmacist, an individual who meets the requirements in paragraph (A)
of rule 3701:1-58-20 and rule 3701:1-58-22 of the Administrative
Code. (3) For an authorized
medical physicist, an individual who meets the requirements in paragraph (A) of
rule 3701:1-58-19 and rule 3701:1-58-22 of the Administrative
Code. (4) An individual who is
identified as an authorized user, an authorized nuclear pharmacist, ophthalmic
physicist, or authorized medical physicist: (a) On a United States nuclear regulatory commission or agreement
state license or other equivalent permit or license recognized by the director
that authorizes the use of radioactive material in medical use or in the
practice of nuclear pharmacy; (b) On a permit issued by a United States nuclear regulatory
commission or agreement state specific license of broad scope that is
authorized to permit the use of radioactive material in medical use or in the
practice of nuclear pharmacy; (c) On a permit issued by a United States nuclear regulatory
commission master material licensee that is authorized to permit the use of
radioactive material in medical use or in the practice of nuclear pharmacy;
or (d) By a commercial nuclear pharmacy that has been authorized to
identify authorized nuclear pharmacists; (C) Before a radiation safety officer is
changed, except as provided in rule 3701:1-58-12 of the Administrative
Code; (D) Before it permits anyone to work as an associate
radiation safety officer, or before the radiation safety officer assigns duties
and tasks to an associate radiation safety officer that differ from those for
which this individual is authorized on the license; (E) Before it receives radioactive material in excess of
the amount or in a different form, or receives a different radionuclide than is
authorized on the license; (F) Before it adds to or changes the areas of use
identified in the application or on the license, except for areas of use where
radioactive material is used only in accordance with either rule 3701:1-58-32
or 3701:1-58-34 of the Administrative Code; (G) Before it changes the address(es) of use identified in
the application or on the license; (H) Before it revises procedures required by rules
3701:1-58-58 and 3701:1-58-64 to 3701:1-58-66 of the Administrative Code, as
applicable, where such revision reduces radiation safety; and (I) Before it receives a sealed source from a different
manufacturer or of a different model number than authorized by its license
unless the sealed source is used for manual brachytherapy, is listed in the
sealed source and device registry, and is in a quantity and for an isotope
authorized by the license.
Last updated November 18, 2022 at 8:28 AM
|
Rule 3701:1-58-09 | Notifications.
Effective:
August 15, 2021
(A) A licensee shall provide the director
a copy of the board certification and the written attestation(s), signed by a
preceptor, the United States nuclear regulatory commission or agreement state
license, the permit issued by a United States nuclear regulatory commission
master material licensee, the permit issued by a United States nuclear
regulatory commission or agreement state licensee of broad scope, or the permit
issued by a United States nuclear regulatory commission master material license
broad scope permittee for each individual no later than thirty days after the
date that the licensee permits the individual to work as an authorized user, an
authorized nuclear pharmacist, ophthalmic physicist, or an authorized medical
physicist, under paragraph (B) of rule 3701:1-58-08 of the Administrative Code.
For individuals permitted to work under paragraph (B)(4) of rule 3701:1-58-08
of the Administrative Code, within the same thirty day time frame, the licensee
shall also provide, as appropriate, verification of completion of; (1) Any additional case
experience required in paragraph (B)(1)(b)(vi) of rule 3701:1-58-40 of the
Administrative Code for an authorized user under rule 3701:1-58-37 of the
Administrative Code; (2) Any additional
training required in paragraph (C) of rule 3701:1-58-71 of the Administrative
Code for an authorized user under rule 3701:1-58-55 of the Administrative Code;
and (3) Any additional
training required in paragraph (C) of rule 3701:1-58-19 of the Administrative
Code for an authorized medical physicist. (B) A licensee shall notify the director
by letter no later than thirty days after: (1) An authorized user,
an authorized nuclear pharmacist, a radiation safety officer, an associate
radiation safety officer, ophthalmic physicist, or an authorized medical
physicist permanently discontinues performance of duties under the license or
has a name change; (2) The licensee permits
an authorized user or an individual qualified to be a radiation safety officer
under rules 3701:1-58-18 and 3701:1-58-22 of the Administrative Code, to
function as a temporary radiation safety officer and to perform the functions
of a radiation safety officer in accordance with paragraph (C) of rule
3701:1-58-12 of the Administrative Code. (3) The licensee's
mailing address changes; (4) The licensee's
name changes, but the name change does not constitute a transfer of control of
the license as described in paragraph (A) of rule 3701:1-40-16 of the
Administrative Code; (5) The licensee has
added to or changed the areas of use identified in the application or on the
license where radioactive material is used in accordance with either rule
3701:1-58-32 or 3701:1-58-34 of the Administrative Code; or (6) The licensee obtains
a sealed source for use in manual brachytherapy from a different manufacturer
or with a different model number than authorized by its license for which it
did not require a license amendment as provided in paragraph (I) of rule
3701:1-58-08 of the Administrative Code. The notification must include the
manufacturer and model number of the sealed source, the isotope, and the
quantity per sealed source. (C) The licensee shall provide the
documents required in this rule to the director either electronically or at the
appropriate address identified in rule 3701:1-40-04 of the Administrative
Code.
Last updated November 18, 2022 at 8:29 AM
|
Rule 3701:1-58-10 | Exemptions regarding type A specific licenses of broad scope.
Effective:
August 15, 2021
A licensee possessing a type A specific license of
broad scope for medical use, issued under rules 3701:1-40-22 and 3701:1-40-23
of the Administrative Code, is exempt from: (A) The provisions of paragraph (D) of
rule 3701:1-58-07 of the Administrative Code regarding the need to file an
amendment to the license for medical use of radioactive material, as described
in rule 3701:1-58-72 of the Administrative Code; (B) The provisions of paragraph (B) of
rule 3701:1-58-08 of the Administrative Code; (C) The provisions of paragraph (F) of
rule 3701:1-58-08 of the Administrative Code regarding additions to or changes
in the areas of use at the addresses identified in the application or on the
license; (D) The provisions of paragraph (A) of
rule 3701:1-58-09 of the Administrative Code; (E) The provisions of paragraph (B)(1) of
rule 3701:1-58-09 of the Administrative Code for an authorized user, an
authorized nuclear pharmacist, ophthalmic physicist, or an authorized medical
physicist; (F) The provisions of paragraph (B)(5) of
rule 3701:1-58-09 of the Administrative Code regarding additions to or changes
in the areas of use identified in the application or on the license where
radioactive material is used in accordance with either rule 3701:1-58-32 or
3701:1-58-34 of the Administrative Code; and (G) The provisions of paragraph (A) of
rule 3701:1-58-17 of the Administrative Code.
Last updated November 18, 2022 at 8:29 AM
|
Rule 3701:1-58-11 | License issuance.
Effective:
October 4, 2010
(A) The director shall issue a license for the medical use of radioactive material if: (1) The applicant has filed documentation in accordance with rule 3701:1-58-07 of the Administrative Code; (2) The applicant has paid any applicable fee as provided in rule 3701:1-38-02 of the Administrative Code; (3) The director finds the applicant equipped and committed to observe the safety standards established by the director for the protection of the public health and safety; and (4) The applicant meets the requirements of Chapter 3701:1-40 and rule 3701:1-38-02 of the Administrative Code. (B) The director shall issue a license for mobile medical service if the applicant: (1) Meets the requirements in paragraph (A) of this rule; and (2) Assures that individuals or human research subjects to whom unsealed radioactive material or radiation from implants containing radioactive material will be administered may be released following treatment in accordance with rule 3701:1-58-30 of the Administrative Code.
Last updated November 18, 2022 at 8:29 AM
|
Rule 3701:1-58-12 | Authority and responsibilities for the radiation protection program.
Effective:
August 15, 2021
(A) In addition to the radiation
protection program requirements of rule 3701:1-38-11 of the Administrative
Code, a licensee's management shall approve in writing: (1) Requests for a
license application, renewal, or amendment before submittal to the
director; (2) Any individual before
allowing that individual to work as an authorized user, authorized nuclear
pharmacist, or authorized medical physicist; and (3) Radiation protection
program changes that do not require a license amendment and are permitted under
rule 3701:1-58-13 of the Administrative Code. (B) A licensee's management shall
appoint a radiation safety officer, who agrees, in writing, to be responsible
for implementing the radiation protection program. The licensee, through the
radiation safety officer, shall ensure that radiation safety activities are
being performed in accordance with licensee-approved procedures and regulatory
requirements. A licensee's management may appoint, in writing, one or more
associate radiation safety officers to support the radiation safety officer.
The radiation safety officer, with written agreement of the licensee's
management, must assign the specific duties and tasks to each associate
radiation safety officer. These duties and tasks are restricted to the types of
use for which the associate radiation safety officer is listed on a license.
The radiation safety officer may delegate duties and tasks to the associate
radiation safety officer but shall not delegate the authority or
responsibilities for implementing the radiation protection
program. (C) For up to sixty days each year, a
licensee may permit an individual qualified to be a radiation safety officer,
under rules 3701:1-58-18 and 3701:1-58-22 of the Administrative Code, to
function as a temporary radiation safety officer and to perform the functions
of a radiation safety officer, as provided in paragraph (G) of this rule, if
the licensee takes the actions required in paragraphs (B), (E), (G), and (H) of
this rule and notifies the director in accordance with paragraph (B) of rule
3701:1-58-09 of the Administrative Code. (D) A licensee may simultaneously appoint
more than one temporary radiation safety officer in accordance with paragraph
(C) of this rule, if needed to ensure that the licensee has a temporary
radiation safety officer that satisfies the requirements to be a radiation
safety officer for each of the different types of uses of radioactive material
permitted by the license. (E) A licensee shall establish the
authority, duties, and responsibilities of the radiation safety officer in
writing. (F) Licensees that are authorized for two
or more different types of uses of radioactive material under rules
3701:1-58-37 to 3701:1-58-52 of the Administrative Code and rules 3701:1-58-55
to 3701:1-58-71 of the Administrative Code, or two or more types of units under
rules 3701:1-58-55 to 3701:1-58-71 of the Administrative Code, shall establish
a radiation safety committee to oversee all uses of radioactive material
permitted by the license. The committee must include an authorized user of each
type of use permitted by the license, the radiation safety officer, a
representative of the nursing service, and a representative of management who
is neither an authorized user nor a radiation safety officer. The committee may
include other members the licensee considers appropriate. (G) A licensee shall provide the
radiation safety officer sufficient authority, organizational freedom, time,
resources, and management prerogative, to: (1) Identify radiation
safety problems; (2) Initiate, recommend,
or provide corrective actions; (3) Stop unsafe
operations; and, (4) Verify implementation
of corrective actions. (H) A licensee shall retain a record of
actions taken under paragraphs (A), (B), and (E) of this rule in accordance
with rule 3701:1-58-73 of the Administrative Code.
Last updated November 18, 2022 at 8:29 AM
|
Rule 3701:1-58-13 | Radiation protection program changes.
Effective:
August 15, 2005
(A) A licensee may revise its radiation protection program without the director's approval if: (1) The revision does not require a license amendment under rule 3701:1-58-08 of the Administrative Code; (2) The revision is in compliance with the regulations and the license; (3) The revision has been reviewed and approved by the radiation safety officer and licensee management; and (4) The affected individuals are instructed on the revised program before the changes are implemented. (B) A licensee shall retain a record of each change in accordance with rule 3701:1-58-74 of the Administrative Code.
Last updated November 18, 2022 at 8:30 AM
|
Rule 3701:1-58-14 | Supervision.
Effective:
August 15, 2005
(A) A licensee that permits the receipt, possession, use, or transfer of radioactive material by an individual under the supervision of an authorized user, as allowed by paragraph (B)(1) of rule 3701:1-58-06 of the Administrative Code, shall: (1) In addition to the requirements in rule 3701:1-38-10 of the Administrative Code, instruct the supervised individual in the licensee's written radiation protection procedures, written directive procedures, regulations of this chapter, and license conditions with respect to the use of radioactive material; and (2) Require the supervised individual to follow the instructions of the supervising authorized user for medical uses of radioactive material, written radiation protection procedures established by the licensee, written directive procedures, regulations of this chapter, and license conditions with respect to the medical use of radioactive material. (B) A licensee that permits the preparation of radioactive material for medical use by an individual under the supervision of an authorized nuclear pharmacist or physician who is an authorized user, as allowed by paragraph (B)(2) of rule 3701:1-58-06 of the Administrative Code shall: (1) In addition to the requirements in rule 3701:1-38-10 of the Administrative Code, instruct the supervised individual in the preparation of radioactive material for medical use, as appropriate to that individual's involvement with radioactive material; and (2) Require the supervised individual to follow the instructions of the supervising authorized user or authorized nuclear pharmacist regarding the preparation of radioactive material for medical use, written radiation protection procedures established by the licensee, the rules of this chapter, and license conditions. (C) A licensee that permits supervised activities under paragraphs (A) and (B) of this rule is responsible for the acts and omissions of the supervised individual.
Last updated November 18, 2022 at 8:30 AM
|
Rule 3701:1-58-15 | Written directives.
Effective:
August 15, 2021
(A) A written directive must be dated and
signed by an authorized user before the administration of iodine-131 sodium
iodide greater than 1.11 megabecquerels (thirty microcuries), any therapeutic
dosage of unsealed radioactive material or any therapeutic dose of radiation
from radioactive material. If, because of the emergent nature of the
patient's condition, a delay in order to provide a written directive would
jeopardize the patient's health, an oral directive is acceptable. The
information contained in the oral directive must be documented as soon as
possible in writing in the patient's record. A written directive must be
prepared within forty-eight hours of the oral directive. (B) The written directive must contain
the patient or human research subject's name and the following
information: (1) For any
administration of quantities greater than 1.11 megabecquerels (thirty
microcuries) of sodium iodide iodine-131: the dosage; (2) For an administration
of a therapeutic dosage of unsealed radioactive material other than sodium
iodide iodine-131: the radioactive drug, dosage, and route of
administration; (3) For gamma
stereotactic radiosurgery: the total dose, treatment site, and values for the
target coordinate settings per treatment for each anatomically distinct
treatment site; (4) For teletherapy: the
total dose, dose per fraction, number of fractions, and treatment
site; (5) For high dose-rate
remote afterloading brachytherapy: the radionuclide, treatment site, dose per
fraction, number of fractions, and total dose; (6) For permanent implant
brachytherapy: (a) Before implantation: treatment site, the radionuclide, and
the total source strength; and (b) After implantation but before the patient leaves the
post-treatment recovery area: the treatment site, the number of sources
implanted, the total source strength implanted, and the date when the licensee
assessed the patient's implantation; or (7) For all other
brachytherapy, including low, medium, and pulsed dose rate remote
afterloaders: (a) Before implantation: The treatment site, radionuclide,
and dose; and (b) After implantation but before completion of the
procedure: The radionuclide; treatment site; number of sources; total source
strength and exposure time (or the total dose); and the date when the licensee
assessed the patient's implantation. (C) A written revision to an existing
written directive may be made if the revision is dated and signed by an
authorized user before the administration of the dosage of unsealed radioactive
material, the brachytherapy dose, the gamma stereotactic radiosurgery dose, the
teletherapy dose, or the next fractional dose. If, because of the
patient's condition, a delay in order to provide a written revision to an
existing written directive would jeopardize the patient's health, an oral
revision to an existing written directive is acceptable. The oral revision must
be documented as soon as possible in the patient's record. A revised
written directive must be signed by the authorized user within forty-eight
hours of the oral revision. (D) The licensee shall retain a copy of
the written directive in accordance with rule 3701:1-58-75 of the
Administrative Code.
Last updated November 18, 2022 at 8:31 AM
|
Rule 3701:1-58-16 | Procedures for administrations requiring a written directive.
Effective:
August 15, 2021
(A) For any administration requiring a
written directive, the licensee shall develop, implement, and maintain written
procedures to provide high confidence that: (1) The patient's or
human research subject's identity is verified before each administration;
and (2) Each administration
is in accordance with the written directive. (B) At a minimum, the procedures required
by paragraph (A) of this rule must address the following items that are
applicable to the licensee's use of radioactive material: (1) Verifying the
identity of the patient or human research subject; (2) Verifying that the
administration is in accordance with the treatment plan, if applicable, and the
written directive; (3) Checking both manual
and computer-generated dose calculations; (4) Verifying that any
computer-generated dose calculations are correctly transferred into the
consoles of therapeutic medical units authorized by rule 3701:1-58-55 or
3701:1-58-72 of the Administrative Code; (5) Determining if a medical event, as defined in rule
3701:1-58-101 of the Administrative Code, has occurred; and (6) Determining, for permanent implant brachytherapy,
within sixty calendar days from the date the implant was performed, the total
source strength administered outside of the treatment site compared to the
total source strength documented in the post-implantation portion of the
written directive, unless a written justification of patient unavailability is
documented. (C) A licensee shall retain a copy of the
procedures required under paragraph (A) of this rule in accordance with rule
3701:1-58-76 of the Administrative Code.
Last updated November 18, 2022 at 8:31 AM
|
Rule 3701:1-58-17 | Suppliers for sealed sources or devices for medical use.
Effective:
December 22, 2008
For medical use, a licensee may only use: (A) Sealed sources or devices manufactured, labeled, packaged, and distributed in accordance with a license issued under Chapter 3701:1-40 and rules 3701:1-38-02 and 3701:1-46-44 of the Administrative Code or equivalent requirements of the United States nuclear regulatory commission or an agreement state; (B) Sealed sources or devices noncommercially transferred from an individual licensed in accordance with rule 3701:1-58-06 of the Administrative Code or a United States nuclear regulatory commission or agreement state medical use licensee; or (C) Teletherapy sources manufactured and distributed in accordance with a license issued under Chapter 3701:1-40 of the Administrative Code or the equivalent requirements of the United States nuclear regulatory commission or an agreement state.
Last updated November 18, 2022 at 8:31 AM
|
Rule 3701:1-58-18 | Training for radiation safety officer and associate radiation safety officer.
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an individual fulfilling the
responsibilities of the radiation safety officer or an individual assigned
duties and tasks as an associate radiation safety officer as provided in rule
3701:1-58-12 of the Administrative Code to be an individual who: (A) Is certified by a specialty board
whose certification process has been recognized by the director, the United
States nuclear regulatory commission, or an agreement state and who meets the
requirements in paragraph (D) of this rule. The names of board certifications
which have been recognized by the director, the United States nuclear
regulatory commission, or an agreement state will be posted on the United
States nuclear regulatory commission's "Medical Uses Licensee
Toolkit" web page at www.nrc.gov. To have its certification process
recognized, a specialty board shall require all candidates for certification
to: (1) (a) Hold a bachelor's or graduate degree from an accredited
college or university in physical science or engineering or biological science
with a minimum of twenty college credits in physical science; (b) Have five or more years of professional experience in health
physics, for which graduate training may be substituted for no more than two
years of the required experience, with at least three years in applied health
physics; and (c) Pass an examination administered by diplomates of the
specialty board, which evaluates knowledge and competence in radiation physics
and instrumentation, radiation protection, mathematics pertaining to the use
and measurement of radioactivity, radiation biology, and radiation dosimetry;
or (2) (a) Hold a master's or doctor's degree in physics,
medical physics, other physical science, engineering, or applied mathematics
from an accredited college or university; (b) Have two years of full-time practical training and/or
supervised experience in medical physics: (i) Under the supervision
of a medical physicist who is certified in medical physics by a specialty board
recognized by the director, United States nuclear regulatory commission, or an
agreement state; or (ii) In clinical nuclear
medicine facilities providing diagnostic and/or therapeutic services under the
direction of physicians who meet the requirements for authorized users in rule
3701:1-58-21, 3701:1-58-36 or rule 3701:1-58-40 of the Administrative Code;
and (c) Pass an examination, administered by diplomates of the
specialty board, that assesses knowledge and competence in clinical diagnostic
radiological or nuclear medicine physics and in radiation safety;
or (B) Has achieved the following
requirements: (1) Has completed a
structured educational program consisting of both: (a) Two hundred hours of classroom and laboratory training in the
following areas: (i) Radiation physics and
instrumentation; (ii) Radiation
protection; (iii) Mathematics
pertaining to the use and measurement of radioactivity; (iv) Radiation biology;
and (v) Radiation dosimetry;
and (b) One year of full-time radiation safety experience under the
supervision of the individual identified as the radiation safety officer on a
United States nuclear regulatory commission or agreement state license, or
permit issued by a United States nuclear regulatory commission master material
licensee, that authorizes similar type(s) of use(s) of radioactive material. An
associate radiation safety officer may provide supervision for those areas for
which the associate radiation safety officer is authorized on a United States
nuclear regulatory commission or agreement state license, or permit issued by a
United States nuclear regulatory commission master material licensee. The
full-time radiation safety experience must involve the following: (i) Shipping, receiving,
and performing related radiation surveys; (ii) Using and performing
checks for proper operation of instruments used to determine the activity of
dosages, survey meters, and instruments used to measure
radionuclides; (iii) Securing and
controlling radioactive material; (iv) Using administrative
controls to avoid mistakes in the administration of radioactive
material; (v) Using procedures to
prevent or minimize radioactive contamination and using proper decontamination
procedures; (vi) Using emergency
procedures to control radioactive material; and (vii) Disposing of
radioactive material; and (2) This individual must
obtain a written attestation, signed by a preceptor radiation safety officer or
associate radiation safety officer who has experience with the radiation safety
aspects of similar types of use of radioactive material for which the
individual is seeking approval as a radiation safety officer or an associate
radiation safety officer. The written attestation must state that the
individual has satisfactorily completed the requirements in paragraphs (B)(1)
and (D) of this rule, and is able to independently fulfill the radiation
safety-related duties as a radiation safety officer or as an associate
radiation safety officer for a medical use license; or (C) (1) Is a medical
physicist who has been certified by a specialty board whose certification
process has been recognized by the director, United States nuclear regulatory
commission, or an agreement state under paragraph (A) of rule 3701:1-58-19 of
the Administrative Code and has experience in radiation safety for similar
types of use of radioactive material for which the licensee is seeking the
approval of the individual as radiation safety officer or an associate
radiation safety officer and who meets the requirements in paragraph (D) of
this rule; or (2) Is an authorized
user, authorized medical physicist, or authorized nuclear pharmacist identified
on a United States nuclear regulatory commission or an agreement state license,
a permit issued by a United States nuclear regulatory commission master
material licensee, a permit issued by a United States nuclear regulatory
commission or an agreement state licensee of broad scope, or a permit issued by
a United States nuclear regulatory commission master material license broad
scope permittee, has experience with the radiation safety aspects of similar
types of use of radioactive material for which the licensee seeks the approval
of the individual as the radiation safety officer or associate radiation safety
officer, and meets the requirements in paragraph (D) of this rule;
or (3) Has experience with
the radiation safety aspects of the types of use of radioactive material for
which the individual is seeking simultaneous approval both as the radiation
safety officer and the authorized user on the same new medical use license or
new medical use permit issued by a United States nuclear regulatory commission
master material licensee. The individual must also meet the requirements in
paragraph (D) of this rule. (D) Has training in the radiation safety, regulatory issues, and
emergency procedures for the types of use for which a licensee seeks approval.
This training requirement may be satisfied by completing training that is
supervised by a radiation safety officer, an associate radiation safety
officer, authorized medical physicist, authorized nuclear pharmacist, or
authorized user, as appropriate, who is authorized for the type(s) of use for
which the licensee is seeking approval.
Last updated May 18, 2023 at 3:27 PM
|
Rule 3701:1-58-19 | Training for an authorized medical physicist.
Effective:
August 15, 2021
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require the authorized medical
physicist to be an individual who: (A) Is certified by a specialty board
whose certification process has been recognized by the director, the United
States nuclear regulatory commission, or an agreement state and who meets the
requirements in paragraph (C) of this rule. The names of board certifications
which have been recognized by the director, the United States nuclear
regulatory commission, or an agreement state will be posted on the United
States nuclear regulatory commission's "Medical Uses Licensee
Toolkit" web page at www.nrc.gov. To have its certification process
recognized, a specialty board shall require all candidates for certification
to: (1) Hold a master's
or doctor's degree in physics, medical physics, other physical science,
engineering, or applied mathematics from an accredited college or
university; (2) Have two years of
full-time practical training and/or supervised experience in medical
physics: (a) Under the supervision of a medical physicist who is certified
in medical physics by a specialty board whose certification process has been
recognized under this rule by the director, the United States nuclear
regulatory commission, or an agreement state; or (b) In clinical radiation facilities providing high-energy,
external beam therapy with photons and electrons with energies greater than or
equal to one million electron volts and brachytherapy services under the
direction of physicians who meet the requirements for authorized users in rule
3701:1-58-21, 3701:1-58-51, or 3701:1-58-71 of the Administrative Code;
and (3) Pass an examination,
administered by diplomates of the specialty board, that assesses knowledge and
competence in clinical radiation therapy, radiation safety, calibration,
quality assurance, and treatment planning for external beam therapy,
brachytherapy, and stereotactic radiosurgery; or (B) (1) Holds a master's
or doctor's degree in physics, medical physics, other physical science,
engineering, or applied mathematics from an accredited college or university;
and has completed one year of full-time training in medical physics and an
additional year of full-time work experience under the supervision of an
individual who meets the requirements for an authorized medical physicist for
the type(s) of use for which the individual is seeking authorization. This
training and work experience must be conducted in clinical radiation facilities
that provide high-energy, external beam therapy with photons and electrons with
energies greater than or equal to one million electron volts and brachytherapy
services and must include: (a) Performing sealed source leak tests and
inventories; (b) Performing decay corrections; (c) Performing full calibration and periodic spot checks of
external beam treatment units, stereotactic radiosurgery units, and remote
afterloading units as applicable; and (d) Conducting radiation surveys around external beam treatment
units, stereotactic radiosurgery units, and remote afterloading units as
applicable; and (2) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraphs (B)(1) and (C) of this rule, and is able to independently fulfill
the radiation safety-related duties as an authorized medical physicist for each
type of therapeutic medical unit for which the individual is requesting
authorized medical physicist status. The written attestation must be signed by
a preceptor authorized medical physicist who meets the requirements in rule
3701:1-58-19 or 3701:1-58-21 of the Administrative Code or equivalent United
States nuclear regulatory commission or agreement state requirements for an
authorized medical physicist for each type of therapeutic medical unit for
which the individual is requesting authorized medical physicist
status. (C) Has training for the type(s) of use
for which authorization is sought that includes hands-on device operation,
safety procedures, clinical use, and the operation of a treatment planning
system. This training requirement may be satisfied by satisfactorily completing
either a training program provided by the vendor or by training supervised by
an authorized medical physicist authorized for the type(s) of use for which the
individual is seeking authorization.
Last updated November 18, 2022 at 8:31 AM
|
Rule 3701:1-58-20 | Training for an authorized nuclear pharmacist.
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require the authorized nuclear
pharmacist to be a pharmacist who: (A) Is certified by a specialty board
whose certification process has been recognized by the director, United States
nuclear regulatory commission, or an agreement state. The names of board
certifications which have been recognized by the director, United States
nuclear regulatory commission, or an agreement state will be posted on the
United States nuclear regulatory commission's "Medical Uses Licensee
Toolkit" web page at www.nrc.gov. To have its certification process
recognized, a specialty board shall require all candidates for certification
to: (1) Have graduated from a
pharmacy program accredited by the "Accreditation Council on
Pharmaceutical Education" (ACPE) (previously named the "American
Council on Pharmaceutical Education") or have passed the "Foreign
Pharmacy Graduate Examination Committee" (FPGEC) examination; (2) Hold a current,
active license to practice pharmacy; (3) Provide evidence of
having acquired at least four thousand hours of training/experience in nuclear
pharmacy practice. Academic training may be substituted for no more than two
thousand hours of the required training and experience; and (4) Pass an examination
in nuclear pharmacy administered by diplomates of the specialty board, that
assesses knowledge and competency in procurement, compounding, quality
assurance, dispensing, distribution, health and safety, radiation safety,
provision of information and consultation, monitoring patient outcomes,
research and development; or (B) Has achieved the following
requirements: (1) Has completed seven
hundred hours in a structured educational program consisting of
both: (a) Two hundred hours of classroom and laboratory training in the
following areas: (i) Radiation physics and
instrumentation; (ii) Radiation
protection; (iii) Mathematics
pertaining to the use and measurement of radioactivity; (iv) Chemistry of
radioactive material for medical use; and (v) Radiation biology;
and (b) Supervised practical experience in a nuclear pharmacy
involving: (i) Shipping, receiving,
and performing related radiation surveys; (ii) Using and performing
checks for proper operation of instruments used to determine the activity of
dosages, survey meters, and, if appropriate, instruments used to measure alpha-
or beta-emitting radionuclides; (iii) Calculating,
assaying, and safely preparing dosages for patients or human research
subjects; (iv) Using administrative
controls to avoid medical events in the administration of radioactive material;
and (v) Using procedures to
prevent or minimize radioactive contamination and using proper decontamination
procedures; and (2) Has obtained written
attestation, signed by a preceptor authorized nuclear pharmacist, that the
individual has satisfactorily completed the requirements in paragraph (B)(1) of
this rule and is able to independently fulfill the radiation safety-related
duties as an authorized nuclear pharmacist.
Last updated May 18, 2023 at 3:27 PM
|
Rule 3701:1-58-21 | Training for experienced radiation safety officer, teletherapy or medical physicist, authorized medical physicist, authorized user, nuclear pharmacist, and authorized nuclear pharmacist.
(A) (1) An individual
identified as a radiation safety officer, a teletherapy or medical physicist,
an authorized medical physicist, a nuclear pharmacist or an authorized nuclear
pharmacist on a United States nuclear regulatory commission or agreement state
license or a permit issued by a United States nuclear regulatory commission or
agreement state broad scope licensee or master material license permit or by a
master material license permittee of broad scope on or before January 14, 2019
need not comply with the training requirements of rule 3701:1-58-18,
3701:1-58-19, or 3701:1-58-20 of the Administrative Code, respectively, except
the radiation safety officers and authorized medical physicists identified in
this paragraph must meet the training requirements in paragraph (D) of rule
3701:1-58-18 of the Administrative Code or paragraph (C) of rule 3701:1-58-19
of the Administrative Code, as appropriate, for any material or uses for which
they were not authorized prior to this date. (2) Any individual
certified by the "American Board of Health Physics" in comprehensive
health physics; "American Board of Radiology"; "American Board
of Nuclear Medicine"; "American Board of Science" in nuclear
medicine; "Board of Pharmaceutical Specialties" in nuclear pharmacy;
"American Board of Medical Physics" in radiation oncology physics;
"Royal College of Physicians and Surgeons of Canada" in nuclear
medicine; "American Osteopathic Board of Radiology"; or
"American Osteopathic Board of Nuclear Medicine" on or before October
24, 2005, need not comply with the training requirements of rule 3701:1-58-18
of the Administrative Code to be identified as a radiation safety officer or as
an associate radiation safety officer on a United States nuclear regulatory
commission or an agreement state license or United States nuclear regulatory
commission master material license permit for those materials and uses that
these individuals performed on or before October 24, 2005. (3) Any individual
certified by the "American Board of Radiology" in therapeutic
radiological physics, Roentgen ray and gamma ray physics, xray and radium
physics, or radiological physics, or certified by the "American Board of
Medical Physics" in radiation oncology physics, on or before October 24,
2005, need not comply with the training requirements for an authorized medical
physicist described in rule 3701:1-58-19 of the Administrative Code, for those
materials and uses that these individuals performed on or before October 24,
2005. (4) A radiation safety
officer, a medical physicist, or a nuclear pharmacist, who used only
accelerator-produced radioactive materials, discrete sources of radium-226, or
both, for medical uses or in the practice of nuclear pharmacy at a government
agency or federally recognized indian tribe before November 30, 2007, or at all
other locations of use before August 8, 2009, or an earlier date as noticed by
the United States nuclear regulatory commission, need not comply with the
training requirements of rule 3701:1-58-18, 3701:1-58-19, or 3701:1-58-20 of
the Administrative Code, respectively, when performing the same uses. A nuclear
pharmacist, who prepared only radioactive drugs containing accelerator-produced
radioactive materials, or a medical physicist, who used only
accelerator-produced radioactive materials, at the locations and time period
identified in this paragraph, qualifies as an authorized nuclear pharmacist or
an authorized medical physicist, respectively, for those materials and uses
performed before these dates, for purposes of this chapter. (B) (1) Physicians, dentists,
or podiatrists identified as authorized users for the medical use of byproduct
material on a license issued by the United States nuclear regulatory commission
or agreement state, a permit issued by a United States nuclear regulatory
commission master material licensee, a permit issued by a United States nuclear
regulatory commission or agreement state broad scope licensee, or a permit
issued by a United States nuclear regulatory commission master material license
broad scope permittee on or before January 14, 2019, who perform only those
medical uses for which they were authorized on or before that date need not
comply with the training requirements of rules 3701:1-58-32 to 3701:1-58-71 of
the Administrative Code. (2) Physicians, dentists,
or podiatrists not identified as authorized users for the medical use of
byproduct material on a license issued by the United States nuclear regulatory
commission or agreement state, a permit issued by a United States nuclear
regulatory commission master material licensee, a permit issued by a United
States nuclear regulatory commission or agreement state broad scope licensee,
or a permit issued in accordance with a United States nuclear regulatory
commission master material broad scope license on or before October 24, 2005,
need not comply with the training requirements of rules 3701:1-58-32 to
3701:1-58-71 of the Administrative Code for those materials and uses that these
individuals performed on or before October 24, 2005, as follows: (a) For uses authorized under rule 3701:1-58-32 of the
Administrative Code or rule 3701:1-58-34 of the Administrative Code, or oral
administration of sodium iodide I131 requiring a written directive for
imaging and localization purposes, a physician who was certified on or before
October 24, 2005, in nuclear medicine by the "American Board of Nuclear
Medicine"; diagnostic radiology by the "American Board of
Radiology"; diagnostic radiology or radiology by the "American
Osteopathic Board of Radiology"; nuclear medicine by the "Royal
College of Physicians and Surgeons of Canada"; or "American
Osteopathic Board of Nuclear Medicine" in nuclear medicine; (b) For uses authorized under rule 3701:1-58-37 of the
Administrative Code, a physician who was certified on or before October 24,
2005, by the "American Board of Nuclear Medicine"; the "American
Board of Radiology" in radiology, therapeutic radiology, or radiation
oncology; nuclear medicine by the "Royal College of Physicians and
Surgeons of Canada"; or the "American Osteopathic Board of
Radiology" after 1984; (c) For uses authorized under rule 3701:1-58-43 of the
Administrative Code or rule 3701:1-58-55 of the Administrative Code, a
physician who was certified on or before October 24, 2005, in radiology,
therapeutic radiology or radiation oncology by the "American Board of
Radiology"; radiation oncology by the "American Osteopathic Board of
Radiology"; radiology, with specialization in radiotherapy, as a British
"Fellow of the Faculty of Radiology" or "Fellow of the Royal
College of Radiology"; or therapeutic radiology by the "Canadian
Royal College of Physicians and Surgeons"; and (d) For uses authorized under rule 3701:1-58-53 of the
Administrative Code, a physician who was certified on or before October 24,
2005, in radiology, diagnostic radiology, therapeutic radiology, or radiation
oncology by the "American Board of Radiology"; nuclear medicine by
the "American Board of Nuclear Medicine"; diagnostic radiology or
radiology by the "American Osteopathic Board of Radiology"; or
nuclear medicine by the "Royal College of Physicians and Surgeons of
Canada." (3) Physicians, dentists,
or podiatrists who used only accelerator-produced radioactive materials,
discrete sources of radium-226, or both, for medical uses performed at a
government agency or federally recognized indian tribe before November 30,
2007, or at all other locations of use before August 8, 2009, or an earlier
date as noticed by the United States nuclear regulatory commission, need not
comply with the training requirements of rules 3701:1-58-32 to 3701:1-58-71 of
the Administrative Code, when performing the same medical uses. A physician,
dentist, or podiatrist, who used only accelerator-produced radioactive
materials, discrete sources of radium-226, or both, for medical uses at the
locations and time period identified in this paragraph, qualifies as an
authorized user for those materials and uses performed before these dates, for
purposes of this chapter. (C) Individuals who need not comply with
training requirements as described in this rule may serve as preceptors for,
and supervisors of, applicants seeking authorization on Ohio radioactive
material licenses for the same uses for which these individuals are
authorized.
Last updated May 18, 2023 at 3:27 PM
|
Rule 3701:1-58-22 | Recentness of training.
Effective:
December 22, 2008
The training and experience specified in rules 3701:1-58-12 to 3701:1-58-21, 3701:1-58-32 to 3701:1-58-71, and 3701:1-58-104 of the Administrative Code must have been obtained within the seven years preceding the date of application or the individual must have had related continuing education and experience since the required training and experience was completed.
Last updated November 18, 2022 at 8:31 AM
|
Rule 3701:1-58-23 | Possession, use, and calibration of instruments used to measure the activity of unsealed radioactive material.
Effective:
August 15, 2005
(A) For direct measurements performed in accordance with rule 3701:1-58-25 of the Administrative Code, a licensee shall possess and use instrumentation to measure the activity of unsealed radioactive material before it is administered to each patient or human research subject. (B) A licensee shall calibrate the instrumentation required in paragraph (A) of this rule in accordance with nationally recognized standards or the manufacturer's instructions. (C) A licensee shall retain a record of each instrument calibration required by this rule in accordance with rule 3701:1-58-77 of the Administrative Code.
Last updated November 18, 2022 at 8:32 AM
|
Rule 3701:1-58-24 | Calibration of survey instruments.
Effective:
October 4, 2010
(A) A licensee shall calibrate the survey instruments used to show compliance with this chapter and Chapter 3701:1-38 of the Administrative Code before first use, annually, and following a repair that affects the calibration. A licensee shall: (1) Calibrate all scales with readings up to ten millisievert (one thousand millirem) per hour with a radiation source; (2) Calibrate two separate readings on each scale or decade that will be used to show compliance; and (3) Conspicuously note on the instrument the date of calibration. (B) A licensee may not use survey instruments if the difference between the indicated exposure rate and the calculated exposure rate is more than twenty per cent. (C) A licensee shall retain a record of each survey instrument calibration in accordance with rule 3701:1-58-78 of the Administrative Code.
Last updated November 18, 2022 at 8:32 AM
|
Rule 3701:1-58-25 | Determination of dosages of unsealed radioactive material for medical use.
Effective:
October 4, 2010
(A) A licensee shall determine and record the activity of each dosage before medical use. (B) For a unit dosage, this determination must be made by: (1) Direct measurement of radioactivity; or (2) A decay correction, based on the activity or activity concentration determined by: (a) A manufacturer or preparer licensed under rule 3701:1-46-43 of the Administrative Code or equivalent United States nuclear regulatory commission, or agreement state requirements; (b) An United States nuclear regulatory commission, or agreement state licensee for use in research in accordance with a radioactive drug research committee-approved protocol or an investigational new drug protocol accepted by United States food and drug administration; or (c) A PET radioactive drug producer licensed under paragraph (I) of rule 3701:1-40-14 of the Administrative Code, or equivalent United States nuclear regulatory commission or agreement state requirements. (C) For other than unit dosages, this determination must be made by: (1) Direct measurement of radioactivity; (2) Combination of measurement of radioactivity and mathematical calculations; or (3) Combination of volumetric measurements and mathematical calculations, based on the measurement made by: (a) A manufacturer or preparer licensed under rule 3701:1-46-43 of the Administrative Code or equivalent United States nuclear regulatory commission or agreement state requirements; or (b) A PET radioactive drug producer licensed under paragraph (I) of rule 3701:1-40-14 of the Administrative Code, or equivalent United States nuclear regulatory commission or agreement state requirements. (D) Unless otherwise directed by the authorized user, a licensee may not use a dosage if the dosage does not fall within the prescribed dosage range or if the dosage differs from the prescribed dosage by more than twenty per cent. (E) A licensee shall retain a record of the dosage determination required by this rule in accordance with rule 3701:1-58-79 of the Administrative Code.
Last updated November 18, 2022 at 8:32 AM
|
Rule 3701:1-58-26 | Authorization for calibration, transmission, and reference sources.
Effective:
October 6, 2022
(A) Any person authorized by rule
3701:1-58-06 of the Administrative Code for medical use of radioactive material
may receive, possess, and use any of the following radioactive material for
check, calibration, transmission, and reference use: (1) Sealed sources, not
exceeding 1.11 gigabecquerels (thirty millicuries) each, manufactured and
distributed by a person licensed under rule 3701:1-46-44 of the Administrative
Code or equivalent United States nuclear regulatory commission, or agreement
state regulations. (2) Sealed sources, not
exceeding 1.11 gigabecquerels (thirty millicuries) each, redistributed by a
licensee authorized to redistribute the sealed sources manufactured and
distributed by a person licensed under rule 3701:1-46-44 of the Administrative
Code or equivalent United States nuclear regulatory commission or agreement
state regulations, providing the redistributed sealed sources are in the
original packaging and shielding and are accompanied by the manufacturer's
approved instructions. (3) Any radioactive
material with a half-life not longer than one hundred twenty days in individual
amounts not to exceed 0.56 gigabecquerels (fifteen millicuries). (4) Any radioactive
material with a half-life longer than one hundred twenty days in individual
amounts not to exceed the smaller of 7.4 megabecquerels (two hundred
microcuries) or one thousand times the quantities in appendix A to rule
3701:1-40-17 of the Administrative Code. (5) Technetium-99m in
amounts as needed. (B) Radioactive material in sealed
sources authorized by this provision shall not be: (1) Used for medical use
as defined in rule 3701:1-38-01 of the Adminstrative Code except in accordance
with the requirements in rule 3701:1-58-53 of the Adminstrative Code;
or (2) Combined (i.e.,
bundled or aggregated) to create an activity greater than the maximum activity
of any single sealed source authorized under this chapter. (C) A licensee using calibration,
transmission, and reference sources in accordance with the requirements in
paragraph (A) or (B) of this rule need not list these sources on a specific
medical use license.
Last updated October 6, 2022 at 8:25 AM
|
Rule 3701:1-58-27 | Requirements for possession of sealed sources and brachytherapy sources.
Effective:
October 4, 2010
(A) A licensee in possession of any sealed source or brachytherapy source shall follow the radiation safety and handling instructions supplied by the manufacturer. (B) A licensee in possession of a sealed source shall: (1) Test the source for leakage before its first use unless the licensee has a certificate from the supplier indicating that the source was tested within six months before transfer to the licensee; and (2) Test the source for leakage at intervals not to exceed six months or at other intervals approved by the director, United States nuclear regulatory commission, or an agreement state. (C) To satisfy the leak test requirements of this rule, the licensee shall measure the sample so that the leak test can detect the presence of one hundred eighty-five becquerels (0.005 microcurie) of radioactive material in the sample. (D) A licensee shall retain leak test records in accordance with paragraph (A) of rule 3701:1-58-80 of the Administrative Code. (E) If the leak test reveals the presence of one hundred eighty-five becquerels (0.005 microcurie) or more of removable contamination, the licensee shall: (1) Immediately withdraw the sealed source from use and store, dispose, or cause it to be repaired in accordance with the requirements in Chapter 3701:1-38 of the Administrative Code, and (2) File a report within five days of the leak test in accordance with rule 3701:1-58-103 of the Administrative Code. (F) A licensee need not perform a leak test on the following sources: (1) Sources containing only radioactive material with a half-life of less than thirty days; (2) Sources containing only radioactive material as a gas; (3) Sources containing 3.7 megabecquerels (one hundred microcuries) or less of beta or gamma-emitting material or 0.37 megabecquerel (ten microcuries) or less of alpha-emitting material; (4) Seeds of iridium-192 encased in nylon ribbon; and (5) Sources stored and not being used. However, the licensee shall test each such source for leakage before any use or transfer unless it has been leak tested within six months before the date of use or transfer. (G) A licensee in possession of sealed sources or brachytherapy sources, except for gamma stereotactic radiosurgery sources, shall conduct a semi-annual physical inventory of all such sources in its possession. The licensee shall retain each inventory record in accordance with paragraph (B) of rule 3701:1-58-80 of the Administrative Code.
Last updated November 18, 2022 at 8:32 AM
|
Rule 3701:1-58-28 | Labeling of vials and syringes.
Effective:
August 15, 2005
Each syringe and vial that contains unsealed radioactive material must be labeled to identify the radioactive drug. Each syringe shield and vial shield must also be labeled unless the label on the syringe or vial is visible when shielded.
Last updated November 18, 2022 at 8:32 AM
|
Rule 3701:1-58-29 | Surveys of ambient radiation exposure rate.
Effective:
August 15, 2005
(A) In addition to the surveys required by Chapter 3701:1-38 of the Administrative Code, a licensee shall survey, with a radiation detection survey instrument at the end of each day of use, the following: (1) All areas where unsealed radioactive material requiring a written directive was prepared for use or administered. This includes all unsealed radiopharmaceuticals prepared for use or administered under rule 3701:1-58-37 of the Administrative Code. (2) All areas where unsealed radioactive material not requiring a written directive was routinely prepared for use or routinely administered. This includes all unsealed radiopharmaceuticals prepared for use or administered under rule 3701:1-58-32 or 3701:1-58-34 of the Administrative Code. (B) A licensee does not need to perform the surveys required by paragraph (A) of this rule in an area(s) where patients or human research subjects are confined when they cannot be released under rule 3701:1-58-30 of the Administrative Code. (C) A licensee shall retain a record of each survey in accordance with rule 3701:1-58-81 of the Administrative Code.
Last updated November 18, 2022 at 8:32 AM
|
Rule 3701:1-58-30 | Release of individuals containing unsealed radioactive material or implants containing radioactive material.
Effective:
October 6, 2022
(A) A licensee may authorize the release
from its control of any individual who has been administered unsealed
radioactive material or implants containing radioactive material if the total
effective dose equivalent to any other individual from exposure to the released
individual is not likely to exceed five millisieverts (0.5 rem). (B) A licensee shall provide the released
individual, or the individual's parent or guardian, with instructions,
including written instructions, on actions recommended to maintain doses to
other individuals as low as is reasonably achievable if the total effective
dose equivalent to any other individual is likely to exceed one millisievert
(0.1 rem). If the total effective dose equivalent to a nursing infant or child
could exceed one millisievert (0.1 rem) assuming there were no interruption of
breast-feeding, the instructions must also include: (1) Guidance on the
interruption or discontinuation of breast-feeding; and (2) Information on the
potential consequences, if any, of failure to follow the guidance. (C) A licensee shall maintain a record of
the basis for authorizing the release of an individual in accordance with
paragraph (A) of rule 3701:1-58-82 of the Administrative Code. (D) The licensee shall maintain a record
of instructions provided to a breast-feeding female in accordance with rule
3701:1-58-82 of the Administrative Code. (E) Any patient administered gamma
emitting radiopharmaceuticals or permanent brachytherapy sources and is
required to be furnished written instructions in accordance with paragraph (B)
of this rule shall be provided a patient release card to include: (1) The patient's
name; (2) The radionuclide
administered and its activity; (3) The facility name
which administered the radionuclide; (4) The date of the
administration of the radionuclide; and (5) The expiration date
of the card. The card is not applicable to those patients who
are institutionalized in facilities such as hospitals, nursing homes,
correctional institutions, etc. or to those patients whose radiation levels do
not exceed one microsievert per hour (0.1 mrem/hr) at one meter.
Last updated October 6, 2022 at 8:25 AM
|
Rule 3701:1-58-31 | Provision of mobile medical service.
Effective:
August 15, 2005
(A) A licensee providing mobile medical service shall: (1) Obtain a letter signed by the management of each client for which services are rendered that permits the use of radioactive material at the client's address and clearly delineates the authority and responsibility of the licensee and the client; (2) Check instruments used to measure the activity of unsealed radioactive material for proper function before medical use at each client's address or on each day of use, whichever is more frequent. At a minimum, the check for proper function required by this paragraph must include a constancy check; (3) Check survey instruments for proper operation with a dedicated check source before use at each client's address; and (4) Before leaving a client's address, survey all areas of use to ensure compliance with the requirements in Chapter 3701:1-38 of the Administrative Code. (B) A mobile medical service may not have radioactive material delivered from the manufacturer or the distributor to the client unless the client has a license allowing possession of the radioactive material. Radioactive material delivered to the client must be received and handled in conformance with the client's license. (C) A licensee providing mobile medical services shall retain the letter required in paragraph (A)(1) of this rule and the record of each survey required in paragraph (A)(4) of this rule in accordance with paragraphs (A) and (B) of rule 3701:1-58-83 of the Administrative Code, respectively.
Last updated November 18, 2022 at 8:33 AM
|
Rule 3701:1-58-32 | Use of unsealed radioactive material for uptake, dilution, and excretion studies for which a written directive is not required.
Effective:
October 4, 2010
Except for quantities that require a written directive under paragraph (B) of rule 3701:1-58-15 of the Administrative Code, a licensee may use any unsealed radioactive material prepared for medical use for uptake, dilution, or excretion studies that is: (A) Obtained from: (1) A manufacturer or preparer licensed under rule 3701:1-46-43 of the Administrative Code or equivalent United States nuclear regulatory commission or agreement state requirements; or (2) A PET radioactive drug producer licensed in accordance with paragraph (I) of rule 3701:1-40-14 of the Administrative Code or equivalent United States nuclear regulatory commission or agreement state requirement; or (B) Excluding production of PET radionuclides, prepared by: (1) An authorized nuclear pharmacist; or (2) A physician who is an authorized user and who meets the requirements specified in rule 3701:1-58-36, or rule 3701:1-58-40 and paragraph (C)(1)(b)(vii) of rule 3701:1-58-36 of the Administrative Code; or (3) An individual under the supervision, as specified in rule 3701:1-58-14 of the Administrative Code, of the authorized nuclear pharmacist in paragraph (B)(1) of this rule or the physician who is an authorized user in paragraph (B)(2) of this rule; or (C) Obtained from and prepared by an United States nuclear regulatory commission or agreement state licensee for use in research in accordance with a radioactive drug research committee-approved protocol or an investigational new drug protocol accepted by United States food and drug administration; or (D) Prepared by the licensee for use in research in accordance with a radioactive drug research committee-approved application or an investigational new drug protocol accepted by United States food and drug administration.
Last updated November 18, 2022 at 8:33 AM
|
Rule 3701:1-58-33 | Training for uptake, dilution, and excretion studies.
Effective:
August 15, 2021
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user of unsealed
radioactive material for the uses authorized under rule 3701:1-58-32 of the
Administrative Code to be a physician who: (A) Is certified by a medical specialty
board whose certification process has been recognized by the director, United
States nuclear regulatory commission, or an agreement state. The names of board
certifications which have been recognized by the director, United States
nuclear regulatory commission, or an agreement state will be posted on the
United States nuclear regulatory commission's "Medical Uses Licensee
Toolkit" web page at www.nrc.gov. To have its certification process
recognized, a specialty board shall require all candidates for certification
to: (1) Complete sixty hours
of training and experience in basic radionuclide handling techniques and
radiation safety applicable to the medical use of unsealed radioactive material
for uptake, dilution, and excretion studies that includes the topics listed in
paragraphs (C)(1)(a) and (C)(1)(b) of this rule; and (2) Pass an examination,
administered by diplomates of the specialty board, that assesses knowledge and
competence in radiation safety, radionuclide handling, and quality control;
or (B) Is an authorized user under this rule
and rule 3701:1-58-36 or 3701:1-58-40 of the Administrative Code or equivalent
United States nuclear regulatory commission or agreement state requirements;
or (C) Has achieved the following
requirements: (1) Has completed sixty
hours of training and experience, including a minimum of eight hours of
classroom and laboratory training, in basic radionuclide handling techniques
applicable to the medical use of unsealed radioactive material for uptake,
dilution, and excretion studies. The training and experience must
include: (a) Classroom and laboratory training in the following
areas: (i) Radiation physics and
instrumentation; (ii) Radiation
protection; (iii) Mathematics
pertaining to the use and measurement of radioactivity; (iv) Chemistry of
radioactive material for medical use; and (v) Radiation biology;
and (b) Work experience, under the supervision of an authorized user
who meets the requirements in this rule, rule 3701:1-58-21, 3701:1-58-36, or
3701:1-58-40 of the Administrative Code or equivalent United States nuclear
regulatory commission or agreement state requirements, involving: (i) Ordering, receiving,
and unpacking radioactive materials safely and performing the related radiation
surveys; (ii) Performing quality
control procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters; (iii) Calculating,
measuring, and safely preparing patient or human research subject
dosages; (iv) Using administrative
controls to prevent a medical event involving the use of unsealed radioactive
material; (v) Using procedures to
contain spilled radioactive material safely and using proper decontamination
procedures; and (vi) Administering
dosages of radioactive drugs to patients or human research subjects;
and (2) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraph (C)(1) of this rule and is able to independently fulfill the
radiation safety-related duties as an authorized user for the medical uses
authorized under rule 3701:1-58-32 of the Administrative Code. The attestation
must be obtained from either: (a) A preceptor authorized user who meets the requirements
in rule 3701:1-58-21, 3701:1-58-33, 3701:1-58-36, or 3701:1-58-40 of the
Administrative Code or equivalent United States nuclear regulatory commission
or agreement state requirements; or (b) A residency program director who affirms in writing
that the attestation represents the consensus of the residency program faculty
where at least one faculty member is an authorized user who meets the
requirements in rule 3701:1-58-21, 3701:1-58-33, 3701:1-58-36, or 3701:1-58-40
of the Administrative Code or equivalent United States nuclear regulatory
commission or agreement state requirements, and concurs with the attestation
provided by the residency program director. The residency training program must
be approved by the residency review committee of the "Accreditation
Council for Graduate Medical Education," the "Royal College of
Physicians and Surgeons of Canada," or the "Council on Postdoctoral
Training of the American Osteopathic Association," and must include
training and experience specified in paragraph (C)(1) of this
rule.
Last updated November 18, 2022 at 8:33 AM
|
Rule 3701:1-58-34 | Use of unsealed radioactive material for imaging and localization studies for which a written directive is not required.
Effective:
October 4, 2010
Except for quantities that require a written directive under paragraph (B) of rule 3701:1-58-15 of the Administrative Code, a licensee may use any unsealed radioactive material prepared for medical use for imaging and localization studies that is: (A) Obtained from: (1) A manufacturer or preparer licensed under rule 3701:1-46-43 of the Administrative Code or equivalent United States nuclear regulatory commission or agreement state requirements; or (2) A PET radioactive drug producer licensed in accordance with paragraph (I) of rule 3701:1-40-14 of the Administrative Code or equivalent United States nuclear regulatory commission or agreement state requirement; or (B) Excluding production of PET radionuclides, prepared by: (1) An authorized nuclear pharmacist; (2) A physician who is an authorized user and who meets the requirements specified in rule 3701:1-58-36 or 3701:1-58-40 and paragraph (C)(1)(b)(vii) of rule 3701:1-58-36 of the Administrative Code; or (3) An individual under the supervision, as specified in rule 3701:1-58-14 of the Administrative Code, of the authorized nuclear pharmacist in paragraph (B)(1) of this rule or the physician who is an authorized user in paragraph (B)(2) of this rule; (C) Obtained from and prepared by an United States nuclear regulatory commission or agreement state licensee for use in research in accordance with a radioactive drug research committee-approved protocol or an investigational new drug protocol accepted by United States food and drug administration; or (D) Prepared by the licensee for use in research in accordance with a radioactive drug research committee-approved application or an investigational new drug protocol accepted by United States food and drug administration.
Last updated November 18, 2022 at 8:33 AM
|
Rule 3701:1-58-35 | Permissible molybdenum-99, strontium-82, and strontium-85 concentrations.
Effective:
August 15, 2021
(A) A licensee may not administer to
humans a radiopharmaceutical that contains: (1) More than 0.15
kilobecquerel of molybdenum-99 per megabecquerel of technetium-99m (0.15
microcurie of molybdenum-99 per millicurie of technetium-99m); or (2) More than 0.02
kilobecquerel of strontium-82 per megabecquerel of rubidium-82 chloride
injection (0.02 microcurie of strontium-82 per millicurie of rubidium-82
chloride); or more than 0.2 kilobecquerel of strontium-85 per megabecquerel of
rubidium-82 chloride injection (0.2 microcurie of strontium-85 per millicurie
of rubidium-82). (B) A licensee that uses
molybdenum-99/technetium-99m generators for preparing a technetium-99m
radiopharmaceutical shall measure the molybdenum-99 concentration of the first
eluate from a generator to demonstrate compliance with paragraph (A) of this
rule. (C) A licensee that uses a
strontium-82/rubidium-82 generator for preparing a rubidium-82
radiopharmaceutical shall, before the first patient use of the day, measure the
concentration of radionuclides strontium-82 and strontium-85 to demonstrate
compliance with paragraph (A) of this rule. (D) If a licensee is required to measure
the molybdenum-99 concentration or strontium-82 and strontium-85
concentrations, the licensee shall retain a record of each measurement in
accordance with rule 3701:1-58-85 of the Administrative Code. (E) The licensee shall report any
measurement that exceeds the limits in paragraph (A) of this rule at the time
of generator elution, in accordance with rule 3701:1-58-105 of the
Administrative Code.
Last updated November 18, 2022 at 8:33 AM
|
Rule 3701:1-58-36 | Training for imaging and localization studies.
Effective:
August 15, 2021
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user of unsealed
radioactive material for the uses authorized in rule 3701:1-58-34 of the
Administrative Code to be a physician who: (A) Is certified by a medical specialty
board whose certification process has been recognized by the director, United
States nuclear regulatory commission, or an agreement state. The names of board
certifications which have been recognized by the director, the United States
nuclear regulatory commission, or an agreement state will be posted on the
United States nuclear regulatory commission's "Medical Uses Licensee
Toolkit" web page at www.nrc.gov. To have its certification process
recognized, a specialty board shall require all candidates for certification
to: (1) Complete seven
hundred hours of training and experience in basic radionuclide handling
techniques and radiation safety applicable to the medical use of unsealed
radioactive material for imaging and localization studies that includes the
topics listed in paragraphs (C)(1)(a) and (C)(1)(b) of this rule;
and (2) Pass an examination,
administered by diplomates of the specialty board, which assesses knowledge and
competence in radiation safety, radionuclide handling, and quality control;
or (B) Is an authorized user under rule
3701:1-58-40 of the Administrative Code and meets the requirements in paragraph
(C)(1)(b)(vii) of rule 3701:1-58-36 of the Administrative Code, or equivalent
United States nuclear regulatory commission or agreement state requirements;
or (C) (1) Has completed seven
hundred hours of training and experience, including a minimum of eighty hours
of classroom and laboratory training, in basic radionuclide handling techniques
applicable to the medical use of unsealed radioactive material for imaging and
localization studies. The training and experience must include, at a
minimum: (a) Classroom and laboratory training in the following
areas: (i) Radiation physics and
instrumentation; (ii) Radiation
protection; (iii) Mathematics
pertaining to the use and measurement of radioactivity; (iv) Chemistry of
radioactive material for medical use; and (v) Radiation biology;
and (b) Work experience, under the supervision of an authorized user,
who meets the requirements in this rule, rule 3701:1-58-21, or 3701:1-58-40 of
the Administrative Code and paragraph (C)(1)(b)(vii) of this rule, or
equivalent United States nuclear regulatory commission or agreement state
requirements. An authorized nuclear pharmacist who meets the requirements in
rule 3701:1-58-20 or 3701:1-58-21 of the Administrative Code may provide the
supervised work experience for paragraph (C)(1)(b)(vii) of this rule. Work
experience must involve: (i) Ordering, receiving,
and unpacking radioactive materials safely and performing the related radiation
surveys; (ii) Performing quality
control procedures on instruments used to determine the activity of dosages and
performing checks for proper operation of survey meters; (iii) Calculating,
measuring, and safely preparing patient or human research subject
dosages; (iv) Using administrative
controls to prevent a medical event involving the use of unsealed radioactive
material; (v) Using procedures to
safely contain spilled radioactive material and using proper decontamination
procedures; (vi) Administering
dosages of radioactive drugs to patients or human research subjects;
and (vii) Eluting generator
systems appropriate for preparation of radioactive drugs for imaging and
localization studies, measuring and testing the eluate for radionuclidic
purity, and processing the eluate with reagent kits to prepare labeled
radioactive drugs; and (2) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraph (C)(1) of this rule and is able to independently fulfill the
radiation safety-related duties as an authorized user for the medical uses
authorized under rules 3701:1-58-32 and 3701:1-58-34 of the Administrative
Code. The attestation must be obtained from either: (a) A preceptor authorized user who meets the requirements
in this rule, rule 3701:1-58-21, or 3701:1-58-40 of the Administrative Code and
paragraph (C)(1)(b)(vii) of this rule, or United States nuclear regulatory
commission or agreement state requirements; or (b) A residency program director who affirms in writing
that the attestation represents the consensus of the residency program faculty
where at least one faculty member is an authorized user who meets the
requirements in this rule, rule 3701:1-58-21, or 3701:1-58-40 of the
Administrative Code and paragraph (C)(1)(b)(vii) of this rule, or United States
nuclear regulatory commission or agreement state requirements, and concurs with
the attestation provided by the residency program director. The residency
training program must be approved by the residency review committee of the
"Accreditation Council for Graduate Medical Education," the
"Royal College of Physicians and Surgeons of Canada," or the
"Council on Postdoctoral Training of the American Osteopathic
Association," and must include training and experience specified in
paragraph (C)(1) of this rule.
Last updated November 18, 2022 at 8:33 AM
|
Rule 3701:1-58-37 | Use of unsealed radioactive material for which a written directive is required.
Effective:
August 15, 2021
A licensee may use any unsealed radioactive
material identified in paragraph (B)(1)(b)(vi) of rule 3701:1-58-40 the
Administrative Code prepared for medical use and for which a written directive
is required that is: (A) Obtained from: (1) A manufacturer or
preparer licensed under rule 3701:1-46-43 of the Administrative Code or
equivalent United States nuclear regulatory commission or agreement state
requirements; or (2) A PET radioactive
drug producer licensed in accordance with paragraph (I) of rule 3701:1-40-14 of
the Administrative Code or equivalent United States nuclear regulatory
commission or agreement state requirement; or (B) Prepared by, excluding production of
PET radionuclides: (1) An authorized nuclear
pharmacist; (2) A physician who is an
authorized user and who meets the requirements specified in rule 3701:1-58-36
or 3701:1-58-40 of the Administrative Code; or (3) An individual under
the supervision, as specified in rule 3701:1-58-14 of the Administrative Code,
of the authorized nuclear pharmacist in paragraph (B)(1) of this rule or the
physician who is an authorized user in paragraph (B)(2) of this rule;
or (C) Obtained from and prepared by an
United States nuclear regulatory commission or agreement state licensee for use
in research in accordance with an investigational new drug protocol accepted by
United States food and drug administration; or (D) Prepared by the licensee for use in
research in accordance with an investigational new drug protocol accepted by
United States food and drug administration.
Last updated November 18, 2022 at 8:34 AM
|
Rule 3701:1-58-38 | Safety instruction for unsealed radioactive material.
Effective:
August 10, 2015
In addition to the requirements of rule 3701:1-38-10 of the Administrative Code, (A) A licensee shall provide radiation safety instruction, initially and at least annually, to personnel caring for patients or human research subjects who cannot be released under rule 3701:1-58-30 of the Administrative Code. To satisfy this requirement, the instruction must be commensurate with the duties of the personnel and include: (1) Patient or human research subject control; (2) Visitor control, including: (a) Routine visitation to hospitalized individuals in accordance with paragraph (A)(1) of rule 3701:1-38-13 of the Administrative Code, and (b) Visitation authorized in accordance with paragraph (C) of rule 3701:1-38-13 of the Administrative Code; (3) Contamination control; (4) Waste control; and (5) Notification of the radiation safety officer, or his or her designee, and an authorized user if the patient or the human research subject has a medical emergency or dies. (B) A licensee shall retain a record of individuals receiving instruction in accordance with rule 3701:1-58-86 of the Administrative Code.
Last updated November 18, 2022 at 8:34 AM
|
Rule 3701:1-58-39 | Safety precautions for unsealed radioactive material.
Effective:
August 10, 2015
(A) For each patient or human research subject who cannot be released under rule 3701:1-58-30 of the Administrative Code, a licensee shall: (1) Quarter the patient or the human research subject either in: (a) A private room with a private sanitary facility; or (b) A room, with a private sanitary facility, with another individual who also has received therapy with unsealed radioactive material and who also cannot be released under rule 3701:1-58-30 of the Administrative Code; (2) Visibly post the patient's or the human research subject's room with a "radioactive materials" sign. (3) Note on the door or in the patient's or human research subject's chart where and how long visitors may stay in the patient's or the human research subject's room; and (4) Either monitor material and items removed from the patient's or the human research subject's room to determine that their radioactivity cannot be distinguished from the natural background radiation level with a radiation detection survey instrument set on its most sensitive scale and with no interposed shielding, or handle the material and items as radioactive waste. (B) A licensee shall notify the radiation safety officer, or his or her designee, and an authorized user as soon as possible if the patient or human research subject has a medical emergency or dies.
Last updated November 18, 2022 at 8:34 AM
|
Rule 3701:1-58-40 | Training for use of unsealed radioactive material for which a written directive is required.
Effective:
October 6, 2022
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user of unsealed
radioactive material for the uses authorized under rule 3701:1-58-37 of the
Administrative Code to be a physician who: (A) Is certified by a medical specialty
board whose certification process has been recognized by the director, United
States nuclear regulatory commission, or an agreement state and who meets the
requirements in paragraph (B)(1)(b)(vi) of this rule. Specialty boards whose
certification processes have been recognized by the director, the United States
nuclear regulatory commission, or an agreement state will be posted on the
United States nuclear regulatory commission's "Medical Uses Licensee
Toolkit" web page at www.nrc.gov. To be recognized, a specialty board
shall require all candidates for certification to: (1) Successfully complete
residency training in a radiation therapy or nuclear medicine training program
or a program in a related medical specialty. These residency training programs
must include seven hundred hours of training and experience as described in
paragraphs (B)(1)(a) to (B)(1)(b)(v) of this rule. Eligible training programs
must be approved by the "Residency Review Committee of the Accreditation
Council for Graduate Medical Education," the "Royal College of
Physicians and Surgeons of Canada," or the "Council on Postdoctoral
Training of the American Osteopathic Association;" and (2) Pass an examination,
administered by diplomates of the specialty board, which tests knowledge and
competence in radiation safety, radionuclide handling, quality assurance, and
clinical use of unsealed radioactive material for which a written directive is
required; or (B) (1) Has completed seven
hundred hours of training and experience, including a minimum of two hundred
hours of classroom and laboratory training, in basic radionuclide handling
techniques applicable to the medical use of unsealed radioactive material
requiring a written directive. The training and experience must
include: (a) Classroom and laboratory training in the following
areas: (i) Radiation physics and
instrumentation; (ii) Radiation
protection; (iii) Mathematics
pertaining to the use and measurement of radioactivity; (iv) Chemistry of
radioactive material for medical use; and (v) Radiation biology;
and (b) Work experience, under the supervision of an authorized user
who meets the requirements in this rule or rule 3701:1-58-21 of the
Administrative Code, or equivalent United States nuclear regulatory commission
or agreement state requirements. A supervising authorized user, who meets the
requirements in paragraph (B) of this rule, must also have experience in
administering dosages in the same dosage category or categories, such as
paragraph (B)(1)(b)(vi) of this rule, as the individual requesting authorized
user status. The work experience must involve: (i) Ordering, receiving,
and unpacking radioactive materials safely and performing the related radiation
surveys; (ii) Performing quality
control procedures on instruments used to determine the activity of dosages,
and performing checks for proper operation of survey meters; (iii) Calculating,
measuring, and safely preparing patient or human research subject
dosages; (iv) Using administrative
controls to prevent a medical event involving the use of unsealed radioactive
material; (v) Using procedures to
contain spilled radioactive material safely and using proper decontamination
procedures; and (vi) Administering
dosages of radioactive drugs to patients or human research subjects from the
three categories in this paragraph. Radioactive drugs containing radionuclides
in categories not included in this paragraph are regulated under rule
3701:1-58-72 of the Administrative Code. This work experience must involve a
minimum of three cases in each of the following categories for which the
individual is requesting authorized user status: (a) Oral administration
of less than or equal to 1.22 gigabecquerels (thirty-three millicuries) of
sodium iodide I-131, for which a written directive is required; (b) Oral administration
of greater than 1.22 gigabecquerels, (thirty-three millicuries) of sodium
iodide I-131. Experience with at least three cases in this paragraph also
satisfies the requirement in paragraph (B)(1)(b)(vi)(a) of this
rule; (c) Parenteral
administration of any radioactive drug that contains a radionuclide that is
primarily used for its electron emission, beta radiation characteristics, alpha
radiation characteristics, or photon energy of less than one hundred fifty keV,
for which a written directive is required; and (2) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraph (B)(1) of this rule and is able to independently fulfill the
radiation safety-related duties as an authorized user for the medical uses
authorized under rule 3701:1-58-37 of the Administrative Code for which the
individual is requesting authorized user status. The attestation must be
obtained from either: (a) A preceptor authorized user who meets the requirements in
rule 3701:1-58-21 of the Administrative Code, rule 3701:1-58-40 of the
Administrative Code, or equivalent United States nuclear regulatory commission
or agreement state requirements and has experience in administering dosages in
the same dosage category or categories as the individual requesting authorized
user status; or (b) A residency program director who affirms in writing that the
attestation represents the consensus of the residency program faculty where at
least one faculty member is an authorized user who meets the requirements in
rule 3701:1-58-21 of the Administrative Code, rule 3701:1-58-40 of the
Administrative Code, or equivalent United States nuclear regulatory commission
or agreement state requirements, has experience in administering dosages in the
same dosage category or categories as the individual requesting authorized user
status, and concurs with the attestation provided by the residency program
director. The residency training program must be approved by the residency
review committee of the "Accreditation Council for Graduate Medical
Education," the "Royal College of Physicians and Surgeons of
Canada," or the "Council on Postdoctoral Training of the American
Osteopathic Association," and must include training and experience
specified in paragraph (B)(1) of this rule.
Last updated October 6, 2022 at 8:25 AM
|
Rule 3701:1-58-41 | Training for the oral administration of sodium iodide iodine-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (thirty-three millicuries).
Effective:
August 15, 2021
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user for the oral
administration of sodium iodide iodine-131 requiring a written directive in
quantities less than or equal to 1.22 gigabecquerels (thirty-three millicuries)
to be a physician who: (A) Is certified by a medical specialty
board whose certification process includes all of the requirements in
paragraphs (C)(1) and (C)(2) of this rule and whose certification process has
been recognized by the director, the United States nuclear regulatory
commission, or an agreement state. The names of board certifications which have
been recognized by the director, the United States nuclear regulatory
commission, or an agreement state will be posted on the United States nuclear
regulatory commission's "Medical Uses Licensee Toolkit" web page
at www.nrc.gov; or (B) Is an authorized user under rule
3701:1-58-40 of the Administrative Code for uses listed in paragraph
(B)(1)(b)(vi)(a) or (B)(1)(b)(vi)(b) of rule 3701:1-58-40 of the Administrative
Code, rule 3701:1-58-42 of the Administrative Code, or equivalent United States
nuclear regulatory commission or agreement state requirements; or (C) Has achieved the following
requirements: (1) Has successfully
completed eighty hours of classroom and laboratory training, applicable to the
medical use of sodium iodide iodine-131 for procedures requiring a written
directive. The training must include: (a) Radiation physics and instrumentation; (b) Radiation protection; (c) Mathematics pertaining to the use and measurement of
radioactivity; (d) Chemistry of radioactive material for medical use;
and (e) Radiation biology; (2) Has work experience,
under the supervision of an authorized user who meets the requirements in rule
3701:1-58-21, 3701:1-58-40, this rule, or rule 3701:1-58-42 of the
Administrative Code, or equivalent United States nuclear regulatory commission
or agreement state requirements. A supervising authorized user who meets the
requirements in paragraph (B) of rule 3701:1-58-40 of the Administrative Code
must have experience in administering dosages as specified in paragraph
(B)(1)(b)(vi)(a) or (B)(1)(b)(vi)(a) of rule 3701:1-58-40 of the Administrative
Code. The work experience must involve: (a) Ordering, receiving, and unpacking radioactive materials
safely and performing the related radiation surveys; (b) Performing quality control procedures on instruments used to
determine the activity of dosages and performing checks for proper operation of
survey meters; (c) Calculating, measuring, and safely preparing patient or human
research subject dosages; (d) Using administrative controls to prevent a medical event
involving the use of radioactive material; (e) Using procedures to contain spilled radioactive material
safely and using proper decontamination procedures; and (f) Administering dosages to patients or human research subjects,
that includes at least three cases involving the oral administration of less
than or equal to 1.22 gigabecquerels (thirty-three millicuries) of sodium
iodide iodine-131; and (3) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraphs (C)(1) and (C)(2) of this rule and is able to independently
fulfill the radiation safety-related duties for oral administration of less
than or equal to 1.22 gigabecquerels (thirty-three millicuries) of sodium
iodide iodine-131 for medical uses authorized under rule 3701:1-58-37 of the
Administrative Code. The attestation must be obtained from either: (a) A preceptor authorized user who meets the requirements
in rule 3701:1-58-21, 3701:1-58-40, this rule, or rule 3701:1-58-42 of the
Administrative Code, or equivalent United States nuclear regulatory commission
or agreement state requirements and has experience in administering dosages as
specified in paragraph (B)(1)(b)(vi)(a) or (B)(1)(b)(vi)(b) of the
Administrative Code; or (b) A residency program director who affirms in writing
that the attestation represents the consensus of the residency program faculty
where at least one faculty member is an authorized user who meets the
requirements in rule 3701:1-58-21, 3701:1-58-40, this rule, or rule
3701:1-58-42 of the Administrative Code, or equivalent United States nuclear
regulatory commission or agreement state requirements, has experience in
administering dosages as specified in paragraph (B)(1)(b)(vi)(a) or
(B)(1)(b)(vi)(b) of the Administrative Code, and concurs with the attestation
provided by the residency program director. The residency training program must
be approved by the residency review committee of the "Accreditation
Council for Graduate Medical Education," the "Royal College of
Physicians and Surgeons of Canada," or the "Council on Postdoctoral
Training of the American Osteopathic Association," and must include
training and experience specified in paragraphs (C)(1) and (C)(2) of this
rule.
Last updated November 18, 2022 at 8:34 AM
|
Rule 3701:1-58-42 | Training for the oral administration of sodium iodide iodine-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (thirty-three millicuries).
Effective:
August 15, 2021
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user for the oral
administration of sodium iodide iodine-131 requiring a written directive in
quantities greater than 1.22 gigabecquerels (thirty-three millicuries) to be a
physician who: (A) Is certified by a medical specialty
board whose certification process includes all of the requirements in
paragraphs (C)(1) and (C)(2) of this rule, and whose certification has been
recognized by the director, the United States nuclear regulatory commission, or
an agreement state. The names of board certifications which have been
recognized by the director, the United States nuclear regulatory commission, or
an agreement state will be posted on the United States nuclear regulatory
commission's "Medical Uses Licensee Toolkit" web page at
www.nrc.gov.; or (B) Is an authorized user under rule
3701:1-58-40 of the Administrative Code, for uses listed in paragraph
(B)(1)(b)(vi)(b) of rule 3701:1-58-40 of the Administrative Code, or equivalent
United States nuclear regulatory commission or agreement state requirements;
or (C) Has achieved the following
requirements: (1) Has successfully
completed eighty hours of classroom and laboratory training, applicable to the
medical use of sodium iodide iodine-131 for procedures requiring a written
directive. The training must include: (a) Radiation physics and instrumentation; (b) Radiation protection; (c) Mathematics pertaining to the use and measurement of
radioactivity; (d) Chemistry of radioactive material for medical use;
and (e) Radiation biology; (2) Has work experience,
under the supervision of an authorized user who meets the requirements in rule
3701:1-58-21, 3701:1-58-40, or this rule of the Administrative Code, or
equivalent United States nuclear regulatory commission or agreement state
requirements. A supervising authorized user who meets the requirements in
paragraph (B) of rule 3701:1-58-40 of the Administrative Code, must have
experience in administering dosages as specified in paragraph (B)(1)(b)(vi)(b)
of rule 3701:1-58-40 of the Administrative Code. The work experience must
involve: (a) Ordering, receiving, and unpacking radioactive materials
safely and performing the related radiation surveys; (b) Performing quality control procedures on instruments used to
determine the activity of dosages and performing checks for proper operation of
survey meters; (c) Calculating, measuring, and safely preparing patient or human
research subject dosages; (d) Using administrative controls to prevent a medical event
involving the use of radioactive material; (e) Using procedures to contain spilled radioactive material
safely and using proper decontamination procedures; and (f) Administering dosages to patients or human research subjects,
that includes at least three cases involving the oral administration of greater
than 1.22 gigabecquerels (thirty-three millicuries) of sodium iodide
iodine-131; and (3) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraphs (C)(1) and (C)(2) of this rule, and is able to independently
fulfill the radiation safety-related duties as an authorized user for oral
administration of greater than 1.22 gigabecquerels (thirty-three millicuries)
of sodium iodide I-131 for medical uses authorized under rule 3701:1-58-37 of
the Administrative Code. The attestation must be obtained from
either: (a) A preceptor authorized user who meets the requirements
in rule 3701:1-58-21, 3701:1-58-40, or this rule of the Administrative Code, or
equivalent United States nuclear regulatory commission or agreement state
requirements, and has experience in administering dosages as specified in
paragraph (B)(1)(b)(vii)(b) of rule 3701:1-58-40 of the Administrative Code;
or (b) A residency program director who affirms in writing
that the attestation represents the consensus of the residency program faculty
where at least one faculty member is an authorized user who meets the
requirements in rule 3701:1-58-21, 3701:1-58-40, or this rule of the
Administrative Code, or equivalent United States nuclear regulatory commission
or agreement state requirements, has experience in administering dosages as
specified in paragraph (B)(1)(b)(vii)(b) of rule 3701:1-58-40 of the
Administrative Code, and concurs with the attestation provided by the residency
program director. The residency training program must be approved by the
residency review committee of the "Accreditation Council for Graduate
Medical Education," the "Royal College of Physicians and Surgeons of
Canada," or the "Council on Postdoctoral Training of the American
Osteopathic Association," and must include training and experience
specified in paragraphs (C)(1) and (C)(2) of this rule.
Last updated November 18, 2022 at 8:34 AM
|
Rule 3701:1-58-43 | Use of sources for manual brachytherapy.
Effective:
August 15, 2021
A licensee shall use only brachytherapy
sources: (A) As approved in the sealed source and device registry
for manual brachytherapy medical use. The manual brachytherapy sources may be
used for manual brachytherapy uses that are not explicitly listed in the sealed
source and device registry, but must be used in accordance with the radiation
safety conditions and limitations described in the sealed source and device
registry; or (B) In research to deliver therapeutic doses for medical
use in accordance with an active investigational device exemption application
accepted by the United States food and drug administration provided the
requirements of paragraph (A) of rule 3701:1-58-17 of the Administrative Code
are met.
Last updated November 18, 2022 at 8:34 AM
|
Rule 3701:1-58-44 | Surveys after source implant and removal.
Effective:
August 15, 2005
(A) The licensee shall make a survey to locate and account for all sources that have not been implanted immediately after implanting sources in a patient or a human research subject. (B) The licensee shall make a survey of the patient or the human research subject with a radiation detection survey instrument to confirm that all sources have been removed immediately after removing the last temporary implant source from a patient or a human research subject. (C) A licensee shall retain a record of the surveys required by paragraphs (A) and (B) of this rule in accordance with rule 3701:1-58-87 of the Administrative Code.
Last updated November 18, 2022 at 8:35 AM
|
Rule 3701:1-58-45 | Brachytherapy sources accountability.
Effective:
August 15, 2005
(A) A licensee shall maintain accountability at all times for all brachytherapy sources in storage or use. (B) As soon as possible after removing sources from a patient or a human research subject, a licensee shall return brachytherapy sources to a secure storage area. (C) A licensee shall maintain a record of the brachytherapy source accountability in accordance with rule 3701:1-58-88 of the Administrative Code.
Last updated November 18, 2022 at 8:35 AM
|
Rule 3701:1-58-46 | Safety instruction for manual brachytherapy.
Effective:
August 10, 2015
In addition to the requirements of rule 3701:1-38-10 of the Administrative Code: (A) The licensee shall provide radiation safety instruction, initially and at least annually, to personnel caring for patients or human research subjects who are receiving brachytherapy and cannot be released under rule 3701:1-58-30 of the Administrative Code. To satisfy this requirement, the instruction must be commensurate with the duties of the personnel and include the: (1) Size and appearance of the brachytherapy sources; (2) Safe handling and shielding instructions; (3) Patient or human research subject control; (4) Visitor control, including both: (a) Routine visitation of hospitalized individuals in accordance with paragraph (A)(1) of rule 3701:1-38-13 of the Administrative Code; and (b) Visitation authorized in accordance with paragraph (C) of rule 3701:1-38-13 of the Administrative Code; and (5) Notification of the radiation safety officer, or his or her designee, and an authorized user if the patient or the human research subject has a medical emergency or dies. (B) A licensee shall retain a record of individuals receiving instruction in accordance with rule 3701:1-58-86 of the Administrative Code.
Last updated November 18, 2022 at 8:35 AM
|
Rule 3701:1-58-47 | Safety precautions for manual brachytherapy.
Effective:
August 10, 2015
(A) For each patient or human research subject who is receiving brachytherapy and cannot be released under rule 3701:1-58-30 of the Administrative Code, a licensee shall: (1) Not quarter the patient or the human research subject in the same room as an individual who is not receiving brachytherapy; (2) Visibly post the patient's or human research subject's room with a "radioactive materials" sign; and (3) Note on the door or in the patient's or human research subject's chart where and how long visitors may stay in the patient's or human research subject's room. (B) A licensee shall have applicable emergency response equipment available near each treatment room to respond to a source: (1) Dislodged from the patient; or (2) Lodged within the patient following removal of the source applicators. (C) A licensee shall notify the radiation safety officer, or his or her designee, and an authorized user as soon as possible if the patient or human research subject has a medical emergency or dies.
Last updated November 18, 2022 at 8:35 AM
|
Rule 3701:1-58-48 | Calibration measurements of brachytherapy sources.
Effective:
October 4, 2010
(A) Before the first medical use of a brachytherapy source, a licensee shall have: (1) Determined the source output or activity using a dosimetry system that meets the requirements of paragraph (A) of rule 3701:1-58-60 of the Administrative Code; (2) Determined source positioning accuracy within applicators; and (3) Used published protocols currently accepted by nationally recognized bodies to meet the requirements of paragraphs (A)(1) and (A)(2) of this rule. (B) Instead of a licensee making its own measurements as required in paragraph (A) of this rule, the licensee may use measurements provided by the source manufacturer or by a calibration laboratory accredited by the "American Association of Physicists in Medicine" (AAPM) that are made in accordance with paragraph (A) of this rule. (C) A licensee shall mathematically correct the outputs or activities determined in paragraph (A) of this rule for radioactive decay at intervals consistent with one percent radioactive decay. (D) A licensee shall retain a record of each calibration in accordance with rule 3701:1-58-89 of the Administrative Code.
Last updated November 18, 2022 at 8:35 AM
|
Rule 3701:1-58-49 | Strontium-90 sources for ophthalmic treatments.
Effective:
August 15, 2021
(A) Licensees who use strontium-90 for ophthalmic
treatments must ensure that certain activities as specified in paragraph (B) of
this rule are performed by either: (1) An authorized medical physicist; or (2) An individual who: (a) Is identified as an
ophthalmic physicist on a specific medical use license issued by the director,
United States nuclear regulatory commission or an agreement state; permit
issued by a United States nuclear regulatory commission or an agreement state
broad scope medical use licensee; medical use permit issued by a United States
nuclear regulatory commission master material licensee; or permit issued by a
United States nuclear regulatory commission master material licensee broad
scope medical use permittee; and (b) Holds a master's
or doctor's degree in physics, medical physics, other physical sciences,
engineering, or applied mathematics from an accredited college or university;
and (c) Has successfully
completed one year of full-time training in medical physics and an additional
year of full-time work experience under the supervision of a medical physicist;
and (d) Has documented
training in: (i) The creation, modification, and completion of written
directives; (ii) Procedures for administrations requiring a written
directive; and (iii) Performing the calibration measurements of
brachytherapy sources as detailed in rule 3701:1-58-48 of the Administrative
Code. (B) The individuals who are identified in paragraph (A) of
this rule must: (1) Calculate the activity of each strontium-90 source that
is used to determine the treatment times for ophthalmic treatments. The decay
must be based on the activity determined under rule 3701:1-58-48 of the
Administrative Code; and (2) Assist the licensee in developing, implementing, and
maintaining written procedures to provide high confidence that the
administration is in accordance with the written directive. These procedures
must include the frequencies that the individual meeting the requirements in
paragraph (A) of this rule will observe treatments, review the treatment
methodology, calculate treatment time for the prescribed dose, and review
records to verify that the administrations were in accordance with the written
directives. (C) Licensees must retain a record of the activity of each
strontium-90 source in accordance with rule 3701:1-58-90 of the Administrative
Code.
Last updated November 18, 2022 at 8:35 AM
|
Rule 3701:1-58-50 | Therapy-related computer systems for manual brachytherapy.
Effective:
August 15, 2005
The licensee shall perform acceptance testing on the treatment planning system of therapy-related computer systems in accordance with published protocols accepted by nationally recognized bodies. At a minimum, the acceptance testing must include, as applicable, verification of: (A) The source-specific input parameters required by the dose calculation algorithm; (B) The accuracy of dose, dwell time, and treatment time calculations at representative points; (C) The accuracy of isodose plots and graphic displays; and (D) The accuracy of the software used to determine sealed source positions from radiographic images.
Last updated November 18, 2022 at 8:36 AM
|
Rule 3701:1-58-51 | Training for use of manual brachytherapy sources.
Effective:
October 6, 2022
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user of a manual
brachytherapy source for the uses authorized under rule 3701:1-58-43 of the
Administrative Code to be a physician who: (A) Is certified by a medical specialty
board whose certification process has been recognized by the director, the
United States nuclear regulatory commission, or an agreement state. The names
of board certifications which have been recognized by the director, the United
States nuclear regulatory commission, or an agreement state will be posted on
the United States nuclear regulatory commission's "Medical Uses
Licensee Toolkit" web page at www.nrc.gov. To have its certification
process recognized, a specialty board shall require all candidates for
certification to: (1) Successfully complete
a minimum of three years of residency training in a radiation oncology program
approved by the "Residency Review Committee of the Accreditation Council
for Graduate Medical Education" or the "Royal College of Physicians
and Surgeons of Canada" or the "Council on Postdoctoral Training of
the American Osteopathic Association"; and (2) Pass an examination,
administered by diplomates of the specialty board, that tests knowledge and
competence in radiation safety, radionuclide handling, treatment planning,
quality assurance, and clinical use of manual brachytherapy; or (B) Has achieved the following
requirements: (1) Has completed a
structured educational program in basic radionuclide handling techniques
applicable to the use of manual brachytherapy sources that
includes: (a) Two hundred hours of classroom and laboratory training in the
following areas: (i) Radiation physics and
instrumentation; (ii) Radiation
protection; (iii) Mathematics
pertaining to the use and measurement of radioactivity; and (iv) Radiation biology;
and (b) Five hundred hours of work experience, under the supervision
of an authorized user who meets the requirements in this rule or rule
3701:1-58-21 of the Administrative Code, or equivalent United States nuclear
regulatory commission or agreement state requirements at a medical facility
authorized to use radioactive materials under rule 3701:1-58-43 of the
Administrative Code, involving: (i) Ordering, receiving,
and unpacking radioactive materials safely and performing the related radiation
surveys; (ii) Checking survey
meters for proper operation; (iii) Preparing,
implanting, and removing brachytherapy sources; (iv) Maintaining running
inventories of material on hand; (v) Using administrative
controls to prevent a medical event involving the use of radioactive material;
and (vi) Using emergency
procedures to control radioactive material; (2) Has completed three
years of supervised clinical experience in radiation oncology, under an
authorized user who meets the requirements in this rule or rule 3701:1-58-21 of
the Administrative Code, or equivalent United States nuclear regulatory
commission or agreement state requirements, as part of a formal training
program approved by the "Residency Review Committee for Radiation Oncology
of the Accreditation Council for Graduate Medical Education" or the
"Royal College of Physicians and Surgeons of Canada" or the
"Council on Postdoctoral Training of the American Osteopathic
Association." This experience may be obtained concurrently with the
supervised work experience required by paragraph (B)(1)(b) of this rule;
and (3) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraphs (B)(1) and (B)(2) of this rule and is able to independently
fulfill the radiation safety-related duties as an authorized user of manual
brachytherapy sources for the medical uses authorized under rule 3701:1-58-43
of the Administrative Code. The attestation must be obtained from
either: (a) A preceptor authorized user who meets the requirements in
this rule or rule 3701:1-58-21 of the Administrative Code, or equivalent United
States nuclear regulatory commission or agreement state requirements;
or (b) A residency program director who affirms in writing that the
attestation represents the consensus of the residency program faculty where at
least one faculty member is an authorized user who meets the requirements in
his rule or rule 3701:1-58-21 of the Administrative Code, or equivalent United
States nuclear regulatory commission or agreement state requirements, and
concurs with the attestation provided by the residency program director. The
residency training program must be approved by the residency review committee
of the "Accreditation Council for Graduate Medical Education," the
"Royal College of Physicians and Surgeons of Canada," or the
"Council on Postdoctoral Training of the American Osteopathic
Association," and must include training and experience specified in
paragraphs (B)(1) and (B)(2) of this rule.
Last updated October 6, 2022 at 8:25 AM
|
Rule 3701:1-58-52 | Training for ophthalmic use of strontium-90.
Effective:
August 15, 2021
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require the authorized user of
strontium-90 for ophthalmic radiotherapy to be a physician who: (A) Is an authorized user under rule
3701:1-58-51 of the Administrative Code, or equivalent United States nuclear
regulatory commission or agreement state requirements; or (B) Has achieved the following
requirements: (1) Has completed
twenty-four hours of classroom and laboratory training applicable to the
medical use of strontium-90 for ophthalmic radiotherapy. The training must
include: (a) Radiation physics and instrumentation; (b) Radiation protection; (c) Mathematics pertaining to the use and measurement of
radioactivity; and (d) Radiation biology; (2) Supervised clinical
training in ophthalmic radiotherapy under the supervision of an authorized user
at a medical institution, clinic, or private practice that includes the use of
strontium-90 for the ophthalmic treatment of five individuals. This supervised
clinical training must involve: (a) Examination of each individual to be treated; (b) Calculation of the dose to be administered; (c) Administration of the dose; and (d) Follow up and review of each individual's case history;
and (3) Has obtained written
attestation, signed by a preceptor authorized user who meets the requirements
in this rule, rule 3701:1-58-21, or 3701:1-58-51 of the Administrative Code, or
equivalent United States nuclear regulatory commission or agreement state
requirements, that the individual has satisfactorily completed the requirements
in paragraphs (B)(1) and (B)(2) of this rule and is able to independently
fulfill the radiation safety-related duties as an authorized user of
strontium-90 for ophthalmic use.
Last updated November 18, 2022 at 8:36 AM
|
Rule 3701:1-58-53 | Use of sealed sources and medical devices for diagnosis.
Effective:
August 15, 2021
(A) A
licensee must use only sealed sources that are not in medical devices for
diagnostic medical uses if the sealed sources are approved in the sealed source
and device registry for diagnostic medicine. The sealed sources may be used for
diagnostic medical uses that are not explicitly listed in the sealed source and
device registry but must be used in accordance with the radiation safety
conditions and limitations described in the sealed source and device
registry. (B) A
licensee must only use medical devices containing sealed sources for diagnostic
medical uses if both the sealed sources and medical devices are approved in the
sealed source and device registry for diagnostic medical uses. The diagnostic
medical devices may be used for diagnostic medical uses that are not explicitly
listed in the sealed source and device registry but must be used in accordance
with the radiation safety conditions and limitations described in the sealed
source and device registry. (C) Sealed sources and devices for diagnostic medical uses
may be used in research in accordance with an active investigational device
exemption (IDE) application accepted by the United States food and drug
administration provided the requirements of paragraph (A) of rule 3701:1-58-17
of the Administrative Code are met.
Last updated November 18, 2022 at 8:36 AM
|
Rule 3701:1-58-54 | Training for use of sealed sources for diagnosis.
Effective:
August 15, 2021
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require the authorized user of a
diagnostic sealed source or a device authorized under rule 3701:1-58-53 of the
Administrative Code to be a physician, dentist, or podiatrist who: (A) Is certified by a specialty board
whose certification process includes all of the requirements in paragraphs (C)
and (D) of this rule and whose certification has been recognized by the
director, United States nuclear regulatory commission, or an agreement state.
The names of board certifications which have been recognized by the director,
the United States nuclear regulatory commission, or an agreement state will be
posted on the United States nuclear regulatory commission's "Medical
Uses Licensee Toolkit" web page at www.nrc.gov; or (B) Is an authorized user for uses listed
in rule 3701:1-58-34 of the Administrative Code, or equivalent United States
nuclear regulatory commission or agreement state requirements; or (C) Has completed eight hours of classroom and laboratory
training in basic radionuclide handling techniques specifically applicable to
the use of the device. The training must include: (1) Radiation physics and
instrumentation; (2) Radiation
protection; (3) Mathematics
pertaining to the use and measurement of radioactivity; and (4) Radiation biology;
and (D) Has completed training in the use of the device for the
uses requested.
Last updated November 18, 2022 at 8:36 AM
|
Rule 3701:1-58-55 | Use of a sealed source in a remote afterloader unit, teletherapy unit, or gamma stereotactic radiosurgery unit.
Effective:
August 15, 2021
(A) A licensee must only use sealed
sources: (1) Approved and as
provided for in the sealed source and device registry in photon emitting remote
afterloader units, teletherapy units, or gamma stereotactic radiosurgery units
to deliver therapeutic doses for medical uses; or (2) In research involving
photon-emitting remote afterloader units, teletherapy units, or gamma
stereotactic radiosurgery units in accordance with an active investigational
device exemption (IDE) application accepted by the United States food and drug
administration provided the requirements of paragraph (A) of rule 3701:1-58-17
of the Administrative Code are met. (B) A licensee must use photon-emitting
remote afterloader units, teletherapy units, or gamma stereotactic radiosurgery
units: (1) Approved in the
sealed source and device registry to deliver a therapeutic dose for medical
use. These devices may be used for therapeutic medical treatments that are not
explicitly provided for in the sealed source and device registry, but must be
used in accordance with radiation safety conditions and limitations described
in the sealed source and device registry; or (2) In research in
accordance with an active investigational device exemption (IDE) application
accepted by the United States food and drug administration provided the
requirements of paragraph (A) of rule 3701:1-58-17 of the Administrative Code
are met.
Last updated November 18, 2022 at 8:36 AM
|
Rule 3701:1-58-56 | Surveys of patients and human research subjects treated with a remote afterloader unit.
Effective:
August 15, 2005
(A) Before releasing a patient or a human research subject from licensee control, a licensee shall survey the patient or the human research subject and the remote afterloader unit with a portable radiation detection survey instrument to confirm that the source(s) has been removed from the patient or human research subject and returned to the safe shielded position. (B) A licensee shall retain a record of these surveys in accordance with rule 3701:1-58-87 of the Administrative Code.
Last updated November 18, 2022 at 8:37 AM
|
Rule 3701:1-58-57 | Installation, maintenance, adjustment, and repair of remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
August 10, 2015
(A) Only a person specifically licensed by the director, the United States nuclear regulatory commission, or an agreement state shall install, maintain, adjust, or repair a remote afterloader unit, teletherapy unit, or gamma stereotactic radiosurgery unit that involves work on the source(s) shielding, the source(s) driving unit, or other electronic or mechanical component that could expose the source(s), reduce the shielding around the source(s), or compromise the radiation safety of the unit or the source(s). (B) Except for low dose-rate remote afterloader units, only a person specifically licensed by the director, United States nuclear regulatory commission, or an agreement state shall install, replace, relocate, or remove a sealed source or source contained in other remote afterloader units, teletherapy units, or gamma stereotactic radiosurgery units. (C) For a low dose-rate remote afterloader unit, only a person specifically licensed by the director, United States nuclear regulatory commission, or an agreement state, or an authorized medical physicist shall install, replace, relocate, or remove a sealed source(s) contained in the unit. (D) A licensee shall retain a record of the installation, maintenance, adjustment, and repair of remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units in accordance with rule 3701:1-58-91 of the Administrative Code.
Last updated November 18, 2022 at 8:37 AM
|
Rule 3701:1-58-58 | Safety procedures and instructions for remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
August 15, 2021
(A) A licensee shall: (1) Secure the unit, the
console, the console keys, and the treatment room when not in use or
unattended; (2) Permit only
individuals approved by the authorized user, radiation safety officer, or
authorized medical physicist to be present in the treatment room during
treatment with the source(s); (3) Prevent dual
operation of more than one radiation producing device in a treatment room if
applicable; and (4) Develop, implement,
and maintain written procedures for responding to an abnormal situation when
the operator is unable to place the source(s) in the shielded position, or
remove the patient or human research subject from the radiation field with
controls from outside the treatment room. These procedures must
include: (a) Instructions for responding to equipment failures and the
names of the individuals responsible for implementing corrective
actions; (b) The process for restricting access to and posting of the
treatment area to minimize the risk of inadvertent exposure; and (c) The names and telephone numbers of the authorized users, the
authorized medical physicist, and the radiation safety officer to be contacted
if the unit or console operates abnormally. (B) A copy of the procedures required by
paragraph (A)(4) of this rule must be physically located at the unit
console. (C) A licensee shall post instructions at
the unit console to inform the operator of: (1) The location of the
procedures required by paragraph (A)(4) of this rule; and (2) The names and
telephone numbers of the authorized users, the authorized medical physicist,
and the radiation safety officer to be contacted if the unit or console
operates abnormally. (D) A licensee shall: (1) Prior to the first
use for patient treatment of a new unit or an existing unit with a manufacturer
upgrade that affects the operation and safety of the unit, ensure that vendor
operational and safety training is provided to all individuals who will operate
the unit. The vendor operational and safety training must be provided by the
device manufacturer or by an individual certified by the device manufacturer to
provide the operational and safety training. (2) Provide operational
and safety instructions initially and at least annually to all individuals who
operate the unit at the facility, as appropriate to the individual's
assigned duties. The instructions shall include instruction in: (a) The procedures identified in paragraph (A)(4) of this
rule; and (b) The operating procedures for the unit. (E) A licensee shall ensure that
operators, authorized medical physicists, and authorized users participate in
drills of the emergency procedures, initially and at least
annually. (F) A licensee shall retain a record of
individuals receiving instruction required by paragraph (D) of this rule, in
accordance with rule 3701:1-58-86 of the Administrative Code. (G) A licensee shall retain a copy of the
procedures required by paragraphs (A)(4) and (D)(2)(b) of this rule in
accordance with rule 3701:1-58-92 of the Administrative Code.
Last updated November 18, 2022 at 8:37 AM
|
Rule 3701:1-58-59 | Safety precautions for remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
August 15, 2005
(A) A licensee shall control access to the treatment room by a door at each entrance. (B) A licensee shall equip each entrance to the treatment room with an electrical interlock system that will: (1) Prevent the operator from initiating the treatment cycle unless each treatment room entrance door is closed; (2) Cause the source(s) to be shielded when an entrance door is opened; and (3) Prevent the source(s) from being exposed following an interlock interruption until all treatment room entrance doors are closed and the source(s) on-off control is reset at the console. (C) A licensee shall require any individual entering the treatment room to assure, through the use of appropriate radiation monitors, that radiation levels have returned to ambient levels. (D) Except for low-dose remote afterloader units, a licensee shall construct or equip each treatment room with viewing and intercom systems to permit continuous observation of the patient or the human research subject from the treatment console during irradiation. (E) For licensed activities where sources are placed within the patient's or human research subject's body, a licensee shall only conduct treatments which allow for expeditious removal of a decoupled or jammed source. (F) In addition to the requirements specified in paragraphs (A) to (E) of this rule, a licensee shall: (1) For medium dose-rate and pulsed dose-rate remote afterloader units, require: (a) An authorized medical physicist and either an authorized user or a physician, under the supervision of an authorized user, who has been trained in the operation and emergency response for the unit to be physically present during the initiation of all patient treatments involving the unit; and (b) An authorized medical physicist and either an authorized user or an individual, under the supervision of an authorized user, who has been trained to remove the source applicator(s) in the event of an emergency involving the unit, to be immediately available during continuation of all patient treatments involving the unit. (2) For high dose-rate remote afterloader units, require: (a) An authorized user and an authorized medical physicist to be physically present during the initiation of all patient treatments involving the unit; and (b) An authorized medical physicist and either an authorized user or a physician, under the supervision of an authorized user, who has been trained in the operation and emergency response for the unit, to be physically present during continuation of all patient treatments involving the unit. (3) For gamma stereotactic radiosurgery units, require an authorized user and an authorized medical physicist to be physically present throughout all patient treatments involving the unit. (4) Notify the radiation safety officer, or his/her designee, and an authorized user as soon as possible if the patient or human research subject has a medical emergency or dies. (G) A licensee shall have applicable emergency response equipment available near each treatment room to respond to a source: (1) Remaining in the unshielded position; or (2) Lodged within the patient following completion of the treatment.
Last updated November 18, 2022 at 8:37 AM
|
Rule 3701:1-58-60 | Dosimetry equipment.
Effective:
October 4, 2010
(A) Except for low dose-rate remote afterloader sources where the source output or activity is determined by the manufacturer, a licensee shall have a calibrated dosimetry system available for use. To satisfy this requirement, one of the following two conditions must be met: (1) The system must have been calibrated using a system or source traceable to the "National Institute of Standards and Technology" (NIST) and published protocols accepted by nationally recognized bodies; or by a calibration laboratory accredited by the "American Association of Physicists in Medicine" (AAPM). The calibration must have been performed within the previous two years and after any servicing that may have affected system calibration; or (2) The system must have been calibrated within the previous four years. Eighteen to thirty months after that calibration, the system must have been intercompared with another dosimetry system that was calibrated within the past twenty-four months by NIST or by a calibration laboratory accredited by the AAPM. The results of the intercomparison must indicate that the calibration factor of the licensee's system had not changed by more than two per cent. The licensee may not use the intercomparison result to change the calibration factor. When intercomparing dosimetry systems to be used for calibrating sealed sources for therapeutic units, the licensee shall use a comparable unit with beam attenuators or collimators, as applicable, and sources of the same radionuclide as the source used at the licensee's facility. (B) The licensee shall have a dosimetry system available for use for spot-check output measurements, if applicable. To satisfy this requirement, the system may be compared with a system that has been calibrated in accordance with paragraph (A) of this rule. This comparison must have been performed within the previous year and after each servicing that may have affected system calibration. The spot-check system may be the same system used to meet the requirement in paragraph (A) of this rule. (C) The licensee shall retain a record of each calibration, intercomparison, and comparison in accordance with rule 3701:1-58-93 of the Administrative Code.
Last updated November 18, 2022 at 8:37 AM
|
Rule 3701:1-58-61 | Full calibration measurements on teletherapy units.
Effective:
October 4, 2010
(A) A licensee authorized to use a teletherapy unit for medical use shall perform full calibration measurements on each teletherapy unit: (1) Before the first medical use of the unit; (2) Before medical use under the following conditions: (a) Whenever spot-check measurements, as described in rule 3701:1-58-64 of the Administrative Code, indicate that the output differs by more than five per cent from the output obtained at the last full calibration corrected mathematically for radioactive decay; (b) Following replacement of the source or following reinstallation of the teletherapy unit in a new location; (c) Following any repair of the teletherapy unit that includes removal of the source or major repair of the components associated with the source exposure assembly; and (3) At intervals not exceeding one year. (B) To satisfy the requirement of paragraph (A) of this rule, full calibration measurements must include determination of: (1) The output within plus or minus three per cent for the range of field sizes and for the distance or range of distances used for medical use; (2) The coincidence of the radiation field and the field indicated by the light beam localizing device; (3) The uniformity of the radiation field and its dependence on the orientation of the useful beam; (4) Timer accuracy and linearity over the range of use; (5) On-off error; and (6) The accuracy of all distance measuring and localization devices in medical use. (C) A licensee shall use the dosimetry system described in paragraph (A) of rule 3701:1-58-60 of the Administrative Code to measure the output for one set of exposure conditions. The remaining radiation measurements required in paragraph (B)(1) of this rule may be made using a dosimetry system that indicates relative dose rates. (D) A licensee shall make full calibration measurements required by paragraph (A) of this rule in accordance with published protocols accepted by nationally recognized bodies. (E) A licensee shall mathematically correct the outputs determined in paragraph (B)(1) of this rule for radioactive decay for intervals not exceeding one month for cobalt-60, six months for cesium-137, or at intervals consistent with one per cent decay for all other nuclides. (F) Full calibration measurements required by paragraph (A) of this rule and radioactive decay corrections required by paragraph (E) of this rule must be performed by the authorized medical physicist. (G) A licensee shall retain a record of each calibration in accordance with rule 3701:1-58-94 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-62 | Full calibration measurements on remote afterloader units.
Effective:
October 4, 2010
(A) A licensee authorized to use a remote afterloader unit for medical use shall perform full calibration measurements on each unit: (1) Before the first medical use of the unit; (2) Before medical use under the following conditions: (a) Following replacement of the source or following reinstallation of the unit in a new location outside the facility; and (b) Following any repair of the unit that includes removal of the source or major repair of the components associated with the source exposure assembly; (3) At intervals not exceeding one quarter for high dose-rate, medium dose-rate, and pulsed dose-rate remote afterloader units with sources whose half-life exceeds seventy-five days; and (4) At intervals not exceeding one year for low dose-rate remote afterloader units. (B) To satisfy the requirement of paragraph (A) of this rule, full calibration measurements must include, as applicable, determination of: (1) The output within five per cent; (2) Source positioning accuracy to within one millimeter; (3) Source retraction with backup battery upon power failure; (4) Length of the source transfer tubes; (5) Timer accuracy and linearity over the typical range of use; (6) Length of the applicators; and (7) Function of the source transfer tubes, applicators, and transfer tube-applicator interfaces. (C) A licensee shall use the dosimetry system described in paragraph (A) of rule 3701:1-58-60 of the Administrative Code to measure the output. (D) A licensee shall make full calibration measurements required by paragraph (A) of this rule in accordance with published protocols accepted by nationally recognized bodies. (E) In addition to the requirements for full calibrations for low dose-rate remote afterloader units in paragraph (B) of this rule, a licensee shall perform an autoradiograph of the source(s) to verify inventory and source(s) arrangement at intervals not exceeding one quarter. (F) For low dose-rate remote afterloader units, a licensee may use measurements provided by the source manufacturer that are made in accordance with paragraphs (A) to (E) of this rule. (G) A licensee shall mathematically correct the outputs determined in paragraph (B)(1) of this rule for radioactive decay at intervals consistent with one per cent radioactive decay. (H) Full calibration measurements required by paragraph (A) of this rule and radioactive decay corrections required by paragraph (G) of this rule must be performed by the authorized medical physicist. (I) A licensee shall retain a record of each calibration in accordance with rule 3701:1-58-94 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-63 | Full calibration measurements on gamma stereotactic radiosurgery units.
Effective:
October 4, 2010
(A) A licensee authorized to use a gamma stereotactic radiosurgery unit for medical use shall perform full calibration measurements on each unit: (1) Before the first medical use of the unit; (2) Before medical use under the following conditions: (a) Whenever spot-check measurements, as described in rule 3701:1-58-66 of the Administrative Code, indicate that the output differs by more than five per cent from the output obtained at the last full calibration corrected mathematically for radioactive decay; (b) Following replacement of the sources or following reinstallation of the gamma stereotactic radiosurgery unit in a new location; and (c) Following any repair of the gamma stereotactic radiosurgery unit that includes removal of the sources or major repair of the components associated with the source assembly; and (3) At intervals not exceeding one year, with the exception that relative helmet factors need only be determined before the first medical use of a helmet and following any damage to a helmet. (B) To satisfy the requirement of paragraph (A) of this rule, full calibration measurements must include determination of: (1) The output within three per cent; (2) Relative helmet factors; (3) Isocenter coincidence; (4) Timer accuracy and linearity over the range of use; (5) On-off error; (6) Trunnion centricity; (7) Treatment table retraction mechanism, using backup battery power or hydraulic backups with the unit off; (8) Helmet microswitches; (9) Emergency timing circuits; and (10) Stereotactic frames and localizing devices (trunnions). (C) A licensee shall use the dosimetry system described in paragraph (A) of rule 3701:1-58-60 of the Administrative Code to measure the output for one set of exposure conditions. The remaining radiation measurements required in paragraph (B)(1) of this rule may be made using a dosimetry system that indicates relative dose rates. (D) A licensee shall make full calibration measurements required by paragraph (A) of this rule in accordance with published protocols accepted by nationally recognized bodies. (E) A licensee shall mathematically correct the outputs determined in paragraph (B)(1) of this rule at intervals not exceeding one month for cobalt-60 and at intervals consistent with one per cent radioactive decay for all other radionuclides. (F) Full calibration measurements required by paragraph (A) of this rule and radioactive decay corrections required by paragraph (E) of this rule must be performed by the authorized medical physicist. (G) A licensee shall retain a record of each calibration in accordance with rule 3701:1-58-94 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-64 | Periodic spot-checks for teletherapy units.
Effective:
August 15, 2005
(A) A licensee authorized to use teletherapy units for medical use shall perform output spot-checks on each teletherapy unit once in each calendar month that include determination of: (1) Timer accuracy, and timer linearity over the range of use; (2) On-off error; (3) The coincidence of the radiation field and the field indicated by the light beam localizing device; (4) The accuracy of all distance measuring and localization devices used for medical use; (5) The output for one typical set of operating conditions measured with the dosimetry system described in paragraph (B) of rule 3701:1-58-60 of the Administrative Code; and (6) The difference between the measurement made in paragraph (A)(5) of this rule and the anticipated output, expressed as a percentage of the anticipated output (i.e., the value obtained at last full calibration corrected mathematically for radioactive decay). (B) A licensee shall perform measurements required by paragraph (A) of this rule in accordance with written procedures established by the authorized medical physicist. That individual need not actually perform the spot-check measurements. (C) A licensee shall have the authorized medical physicist review the results of each spot-check within fifteen days. The authorized medical physicist shall notify the licensee as soon as possible in writing of the results of each spot-check. (D) A licensee authorized to use a teletherapy unit for medical use shall perform safety spot-checks of each teletherapy facility once in each calendar month and after each source installation to assure proper operation of: (1) Electrical interlocks at each teletherapy room entrance; (2) Electrical or mechanical stops installed for the purpose of limiting use of the primary beam of radiation (restriction of source housing angulation or elevation, carriage or stand travel and operation of the beam on-off mechanism); (3) Source exposure indicator lights on the teletherapy unit, on the control console, and in the facility; (4) Viewing and intercom systems; (5) Treatment room doors from inside and outside the treatment room; and (6) Electrically assisted treatment room doors with the teletherapy unit electrical power turned off. (E) If the results of the checks required in paragraph (D) of this rule indicate the malfunction of any system, a licensee shall lock the control console in the off position and not use the unit except as may be necessary to repair, replace, or check the malfunctioning system. (F) A licensee shall retain a record of each spot-check required by paragraphs (A) and (D) of this rule, and a copy of the procedures required by paragraph (B) of this rule, in accordance with rule 3701:1-58-95 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-65 | Periodic spot-checks for remote afterloader units.
Effective:
August 15, 2005
(A) A licensee authorized to use a remote afterloader unit for medical use shall perform spot-checks of each remote afterloader facility and on each unit: (1) Before the first use on any given day that a high dose-rate, medium dose-rate, or pulsed dose-rate remote afterloader is in operation; (2) Before each patient treatment with a low dose-rate remote afterloader unit; and (3) After each source installation. (B) A licensee shall perform the measurements required by paragraph (A) of this rule in accordance with written procedures established by the authorized medical physicist. That individual need not actually perform the spot-check measurements. (C) A licensee shall have the authorized medical physicist review the results of each spot-check within fifteen days. The authorized medical physicist shall notify the licensee as soon as possible in writing of the results of each spot-check. (D) To satisfy the requirements of paragraph (A) of this rule, spot-checks must, at a minimum, assure proper operation of: (1) Electrical interlocks at each remote afterloader unit room entrance; (2) Source exposure indicator lights on the remote afterloader unit, on the control console, and in the facility; (3) Viewing and intercom systems in each high dose-rate, medium dose-rate, and pulsed dose-rate remote afterloader facility; (4) Emergency response equipment; (5) Radiation monitors used to indicate the source position; (6) Timer accuracy; (7) Clock (date and time) in the unit's computer; and (8) Decayed source(s) activity in the unit's computer. (E) If the results of the checks required in paragraph (D) of this rule indicate the malfunction of any system, a licensee shall lock the control console in the off position and not use the unit except as may be necessary to repair, replace, or check the malfunctioning system. (F) A licensee shall retain a record of each check required by paragraph (D) of this rule and a copy of the procedures required by paragraph (B) of this rule in accordance with rule 3701:1-58-96 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-66 | Periodic spot-checks for gamma stereotactic radiosurgery units.
Effective:
August 15, 2005
(A) A licensee authorized to use a gamma stereotactic radiosurgery unit for medical use shall perform spot-checks of each gamma stereotactic radiosurgery facility and on each unit: (1) Monthly; (2) Before the first use of the unit on a given day; and (3) After each source installation. (B) A licensee shall: (1) Perform the measurements required by paragraph (A) of this rule in accordance with written procedures established by the authorized medical physicist. That individual need not actually perform the spot-check measurements. (2) Have the authorized medical physicist review the results of each spot-check within fifteen days. The authorized medical physicist shall notify the licensee as soon as possible in writing of the results of each spot-check. (C) To satisfy the requirements of paragraph (A)(1) of this rule, spot-checks must, at a minimum: (1) Assure proper operation of: (a) Treatment table retraction mechanism, using backup battery power or hydraulic backups with the unit off; (b) Helmet microswitches; (c) Emergency timing circuits; and (d) Stereotactic frames and localizing devices (trunnions). (2) Determine: (a) The output for one typical set of operating conditions measured with the dosimetry system described in paragraph (B) of rule 3701:1-58-60 of the Administrative Code; (b) The difference between the measurement made in paragraph (C)(2)(a) of this rule and the anticipated output, expressed as a percentage of the anticipated output (i.e., the value obtained at last full calibration corrected mathematically for radioactive decay); (c) Source output against computer calculation; (d) Timer accuracy and linearity over the range of use; (e) On-off error; and (f) Trunnion centricity. (D) To satisfy the requirements of paragraphs (A)(2) and (A)(3) of this rule, spot-checks must assure proper operation of: (1) Electrical interlocks at each gamma stereotactic radiosurgery room entrance; (2) Source exposure indicator lights on the gamma stereotactic radiosurgery unit, on the control console, and in the facility; (3) Viewing and intercom systems; (4) Timer termination; (5) Radiation monitors used to indicate room exposures; and (6) Emergency off buttons. (E) A licensee shall arrange for the repair of any system identified in paragraph (C) of this rule that is not operating properly as soon as possible. (F) If the results of the checks required in paragraph (D) of this rule indicate the malfunction of any system, a licensee shall lock the control console in the off position and not use the unit except as may be necessary to repair, replace, or check the malfunctioning system. (G) A licensee shall retain a record of each check required by paragraphs (C) and (D) of this rule and a copy of the procedures required by paragraph (B) of this rule in accordance with rule 3701:1-58-97 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-67 | Additional technical requirements for mobile remote afterloader units.
Effective:
August 15, 2005
(A) A licensee providing mobile remote afterloader service shall: (1) Check survey instruments before medical use at each address of use or on each day of use, whichever is more frequent; and (2) Account for all sources before departure from a client's address of use. (B) In addition to the periodic spot-checks required by rule 3701:1-58-65 of the Administrative Code, a licensee authorized to use mobile afterloaders for medical use shall perform checks on each remote afterloader unit before use at each address of use. At a minimum, checks must be made to verify the operation of: (1) Electrical interlocks on treatment area access points; (2) Source exposure indicator lights on the remote afterloader unit, on the control console, and in the facility; (3) Viewing and intercom systems; (4) Applicators, source transfer tubes, and transfer tube-applicator interfaces; (5) Radiation monitors used to indicate room exposures; (6) Source positioning (accuracy); and (7) Radiation monitors used to indicate whether the source has returned to a safe shielded position. (C) In addition to the requirements for checks in paragraph (B) of this rule, a licensee shall ensure overall proper operation of the remote afterloader unit by conducting a simulated cycle of treatment before use at each address of use. (D) If the results of the checks required in paragraph (B) of this rule indicate the malfunction of any system, a licensee shall lock the control console in the off position and not use the unit except as may be necessary to repair, replace, or check the malfunctioning system. (E) A licensee shall retain a record of each check required by paragraph (B) of this rule in accordance with rule 3701:1-58-98 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-68 | Radiation surveys for remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
October 4, 2010
(A) In addition to the survey requirement in rule 3701:1-38-14 of the Administrative Code, a person subject to rules 3701:1-58-55 to 3701:1-58-71 of the Administrative Code shall make surveys to ensure that the maximum radiation levels and average radiation levels from the surface of the main source safe with the source(s) in the shielded position do not exceed the levels stated in the sealed source and device registry. (B) The licensee shall make the survey required by paragraph (A) of this rule at installation of a new source and following repairs to the source(s) shielding, the source(s) driving unit, or other electronic or mechanical component that could expose the source, reduce the shielding around the source(s), or compromise the radiation safety of the unit or the source(s). (C) A licensee shall retain a record of the radiation surveys required by paragraph (A) of this rule in accordance with rule 3701:1-58-99 of the Administrative Code.
Last updated November 18, 2022 at 8:38 AM
|
Rule 3701:1-58-69 | Five-year inspection for teletherapy and gamma stereotactic radiosurgery units.
Effective:
August 15, 2021
(A) A licensee shall have each
teletherapy unit and gamma stereotactic radiosurgery unit fully inspected and
serviced during source replacement, to assure proper functioning of the source
exposure mechanism and other safety components. The interval between each
full-inspection servicing shall not exceed five years for each teletherapy unit
and shall not exceed seven years for each gamma stereotactic radiosurgery
unit. (B) This inspection and servicing may
only be performed by persons specifically licensed to do so by the director,
the United States nuclear regulatory commission, or an agreement
state. (C) A licensee shall keep a record of the
inspection and servicing in accordance with rule 3701:1-58-100 of the
Administrative Code.
Last updated November 18, 2022 at 8:39 AM
|
Rule 3701:1-58-70 | Therapy-related computer systems for remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
August 15, 2005
The licensee shall perform acceptance testing on the treatment planning system of therapy-related computer systems in accordance with published protocols accepted by nationally recognized bodies. At a minimum, the acceptance testing must include, as applicable, verification of: (A) The source-specific input parameters required by the dose calculation algorithm; (B) The accuracy of dose, dwell time, and treatment time calculations at representative points; (C) The accuracy of isodose plots and graphic displays; (D) The accuracy of the software used to determine sealed source positions from radiographic images; and (E) The accuracy of electronic transfer of the treatment delivery parameters to the treatment delivery unit from the treatment planning system.
Last updated November 18, 2022 at 8:39 AM
|
Rule 3701:1-58-71 | Training for use of remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
October 6, 2022
Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user of a sealed
source for a use authorized under rule 3701:1-58-55 of the Administrative Code
to be a physician who: (A) Is certified by a medical specialty
board whose certification process has been recognized by the director, the
United States nuclear regulatory commission, or an agreement state and who
meets the requirements in paragraph (C) of this rule. The names of board
certifications which have been recognized by the director, the United States
nuclear regulatory commission, or an agreement state will be posted on the
United States nuclear regulatory commission's "Medical Uses Licensee
Toolkit" web page at www.nrc.gov. To have its certification process
recognized, a specialty board shall require all candidates for certification
to: (1) Successfully complete
a minimum of three years of residency training in a radiation therapy program
approved by the "Residency Review Committee of the Accreditation Council
for Graduate Medical Education" or the "Royal College of Physicians
and Surgeons of Canada" or the "Council on Postdoctoral Training of
the American Osteopathic Association"; and (2) Pass an examination,
administered by diplomates of the specialty board, which tests knowledge and
competence in radiation safety, radionuclide handling, treatment planning,
quality assurance, and clinical use of stereotactic radiosurgery, remote
afterloaders and external beam therapy; or (B) Has achieved the following
requirements: (1) Has completed a
structured educational program in basic radionuclide techniques applicable to
the use of a sealed source in a therapeutic medical unit that
includes: (a) Two hundred hours of classroom and laboratory training in the
following areas: (i) Radiation physics and
instrumentation; (ii) Radiation
protection; (iii) Mathematics
pertaining to the use and measurement of radioactivity; and (iv) Radiation biology;
and (b) Five hundred hours of work experience, under the supervision
of an authorized user who meets the requirements in this rule or rule
3701:1-58-21 of the Administrative Code, or equivalent United States nuclear
regulatory commission or agreement state requirements, at a medical facility
that is authorized to use radioactive materials in rule 3701:1-58-55 of the
Administrative Code, involving: (i) Reviewing full
calibration measurements and periodic spot-checks; (ii) Preparing treatment
plans and calculating treatment doses and times; (iii) Using
administrative controls to prevent a medical event involving the use of
radioactive material; (iv) Implementing
emergency procedures to be followed in the event of the abnormal operation of
the medical unit or console; (v) Checking and using
survey meters; and (vi) Selecting the proper
dose and how it is to be administered; (2) Has completed three
years of supervised clinical experience in radiation therapy, under an
authorized user who meets the requirements in this rule or rule 3701:1-58-21 of
the Administrative Code, or equivalent United States nuclear regulatory
commission or agreement state requirements, as part of a formal training
program approved by the "Residency Review Committee for Radiation Oncology
of the Accreditation Council for Graduate Medical Education" or the
"Royal College of Physicians and Surgeons of Canada" or the
"Council on Postdoctoral Training of the American Osteopathic
Association." This experience may be obtained concurrently with the
supervised work experience required by paragraph (B)(1)(b) of this rule;
and (3) Has obtained written
attestation that the individual has satisfactorily completed the requirements
in paragraphs (B)(1), (B)(2), and (C) of this rule, and is able to
independently fulfill the radiation safety-related duties as an authorized user
of each type of therapeutic medical unit for which the individual is requesting
authorized user status. The attestation must be obtained from
either: (a) A preceptor authorized user who meets the requirements in
this rule, rule 3701:1-58-21 of the Administrative Code, or equivalent United
States nuclear regulatory commission or agreement state requirements for the
type(s) of therapeutic medical unit for which the individual is requesting
authorized user status; or (b) A residency program director who affirms in writing that the
attestation represents the consensus of the residency program faculty where at
least one faculty member is an authorized user who meets the requirements in
this rule, rule 3701:1-58-21 of the Administrative Code, or equivalent United
States nuclear regulatory commission or agreement state requirements, for the
type(s) of therapeutic medical unit for which the individual is requesting
authorized user status, and concurs with the attestation provided by the
residency program director. The residency training program must be approved by
the residency review committee of the "Accreditation Council for Graduate
Medical Education," the "Royal College of Physicians and Surgeons of
Canada," or the "Council on Postdoctoral Training of the American
Osteopathic Association," and must include training and experience
specified in paragraphs (B)(1) and (B)(2) of this rule. (C) Has received training in device
operation, safety procedures, and clinical use for the type(s) of use for which
authorization is sought. This training requirement may be satisfied by
satisfactory completion of a training program provided by the vendor for new
users or by receiving training supervised by an authorized user or authorized
medical physicist, as appropriate, who is authorized for the type(s) of use for
which the individual is seeking authorization.
Last updated October 6, 2022 at 8:25 AM
|
Rule 3701:1-58-72 | Other medical uses of radioactive material or radiation from radioactive material.
Effective:
August 15, 2005
A licensee may use radioactive material or a radiation source approved for medical use which is not specifically addressed in rules 3701:1-58-32, 3701:1-58-34, 3701:1-58-37, 3701:1-58-43, 3701:1-58-53 and 3701:1-58-55 of the Administrative Code if: (A) The applicant or licensee has submitted the information required by paragraphs (B) to (D) of rule 3701:1-58-07 of the Administrative Code; and (B) The applicant or licensee has received written approval from the director in a license or license amendment and uses the material in accordance with the regulations and specific conditions the director considers necessary for the medical use of the material.
Last updated November 18, 2022 at 8:39 AM
|
Rule 3701:1-58-73 | Records of authority and responsibilities for radiation protection programs.
Effective:
August 15, 2021
(A) A licensee shall retain a record of
actions taken by the licensee's management in accordance with paragraph
(A) of rule 3701:1-58-12 of the Administrative Code for five years. The record
must include a summary of the actions taken and a signature of licensee
management. (B) The licensee shall retain a record of
the authority, duties, and responsibilities of the radiation safety officer as
required by paragraph (E) of rule 3701:1-58-12 of the Administrative Code, and
a signed copy of each radiation safety officer's agreement to be
responsible for implementing the radiation safety program, as required by
paragraph (B) of rule 3701:1-58-12 of the Administrative Code, for the duration
of the license. The records must include the signature of the radiation safety
officer and licensee management. (C) For each associate radiation safety
officer appointed under paragraph (B) of rule 3701:1-58-12 of the
Administrative Code, the licensee shall retain, for five years after the
associate radiation safety officer is removed from the license, a copy of the
written document appointing the associate radiation safety officer signed by
the licensee's management.
Last updated November 18, 2022 at 8:39 AM
|
Rule 3701:1-58-74 | Records of radiation protection program changes.
Effective:
October 4, 2010
A licensee shall retain a record of each radiation protection program change made in accordance with paragraph (A) of rule 3701:1-58-13 of the Administrative Code for five years. The record must include a copy of the old and new procedures, the effective date of the change, and the signature of the licensee management that reviewed and approved the change.
Last updated November 18, 2022 at 8:39 AM
|
Rule 3701:1-58-75 | Records of written directives.
Effective:
August 15, 2005
For purposes of this chapter, a licensee shall retain a copy of each written directive as required by rule 3701:1-58-15 of the Administrative Code for three years.
Last updated November 18, 2022 at 8:39 AM
|
Rule 3701:1-58-76 | Records for procedures for administrations requiring a written directive.
Effective:
August 15, 2005
For purposes of this chapter, a licensee shall retain a copy of the procedures required by paragraph (A) of rule 3701:1-58-16 of the Administrative Code for the duration of the license.
Last updated November 18, 2022 at 8:39 AM
|
Rule 3701:1-58-77 | Records of calibrations of instruments used to measure the activity of unsealed radioactive material.
Effective:
August 15, 2005
A licensee shall maintain a record of instrument calibrations required by rule 3701:1-58-23 of the Administrative Code for three years. The records must include the model and serial number of the instrument, the date of the calibration, the results of the calibration, and the name of the individual who performed the calibration.
Last updated November 18, 2022 at 8:40 AM
|
Rule 3701:1-58-78 | Records of radiation survey instrument calibrations.
Effective:
August 15, 2005
A licensee shall maintain a record of radiation survey instrument calibrations required by rule 3701:1-58-24 of the Administrative Code for three years. The record must include the model and serial number of the instrument, the date of the calibration, the results of the calibration, and the name of the individual who performed the calibration.
Last updated November 18, 2022 at 8:40 AM
|
Rule 3701:1-58-79 | Records of dosages of unsealed radioactive material for medical use.
Effective:
October 4, 2010
(A) For purposes of this chapter, a licensee shall maintain a record of dosage determinations required by rule 3701:1-58-25 of the Administrative Code for three years. (B) The record must contain: (1) The radiopharmaceutical; (2) The patient's or human research subject's name, or identification number if one has been assigned; (3) The prescribed dosage, the determined dosage, or a notation that the total activity is less than 1.1 megabecquerels (thirty microcuries); (4) The date and time of the dosage determination; and (5) The name of the individual who determined the dosage.
Last updated November 18, 2022 at 8:40 AM
|
Rule 3701:1-58-80 | Records of leaks tests and inventory of sealed sources and brachytherapy sources.
Effective:
August 15, 2005
(A) A licensee shall retain records of leak tests required by paragraph (B) of rule 3701:1-58-27 of the Administrative Code for three years. The records must include the model number, and serial number if one has been assigned, of each source tested; the identity of each source by radionuclide and its estimated activity; the results of the test; the date of the test; and the name of the individual who performed the test. (B) A licensee shall retain records of the semi-annual physical inventory of sealed sources and brachytherapy sources required by paragraph (G) of rule 3701:1-58-27 of the Administrative Code for three years. The inventory records must contain the model number of each source, and serial number if one has been assigned, the identity of each source by radionuclide and its nominal activity, the location of each source, and the name of the individual who performed the inventory.
Last updated November 18, 2022 at 8:40 AM
|
Rule 3701:1-58-81 | Records of surveys for ambient radiation exposure rate.
Effective:
August 15, 2005
A licensee shall retain a record of each survey required by rule 3701:1-58-29 of the Administrative Code for three years. The record must include the date of the survey, the results of the survey, the instrument used to make the survey, and the name of the individual who performed the survey.
Last updated November 18, 2022 at 8:40 AM
|
Rule 3701:1-58-82 | Records of the release of individuals containing unsealed radioactive material or implants containing radioactive material.
Effective:
October 4, 2010
(A) A licensee shall retain a record of the basis for authorizing the release of an individual in accordance with rule 3701:1-58-30 of the Administrative Code, if the total effective dose equivalent is calculated by: (1) Using the retained activity rather than the activity administered; (2) Using an occupancy factor less than 0.25 at one meter; (3) Using the biological or effective half-life; or (4) Considering the shielding by tissue. (B) A licensee shall retain a record that the instructions required by paragraph (B) of rule 3701:1-58-30 of the Administrative Code were provided to a breast-feeding female if the radiation dose to the infant or child from continued breast feeding could result in a total effective dose equivalent exceeding five millisieverts (0.5 rem). (C) For purposes of this chapter, the records required by paragraphs (A) and (B) of this rule must be retained for three years after the date of release of the individual.
Last updated November 18, 2022 at 8:40 AM
|
Rule 3701:1-58-83 | Records of mobile medical services.
Effective:
August 15, 2005
(A) A licensee shall retain a copy of each letter that permits the use of radioactive material at a client's address, as required by paragraph (A)(1) of rule 3701:1-58-31 of the Administrative Code. Each letter must clearly delineate the authority and responsibility of the licensee and the client and must be retained for three years after the last provision of service. (B) A licensee shall retain the record of each survey required by paragraph (A)(4) of rule 3701:1-58-31 of the Administrative Code for three years. The record must include the date of the survey, the results of the survey, the instrument used to make the survey, and the name of the individual who performed the survey.
Last updated November 18, 2022 at 8:40 AM
|
Rule 3701:1-58-84 | Records of decay-in-storage.
Effective:
August 15, 2005
A licensee shall maintain records of the disposal of licensed materials, as required by rule 3701:1-38-19 of the Administrative Code, for three years. The record must include the date of the disposal, the survey instrument used, the background radiation level, the radiation level measured at the surface of each waste container, and the name of the individual who performed the survey.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-85 | Records of molybdenum-99, strontium-82, and strontium-85 concentrations.
Effective:
October 4, 2010
A licensee shall maintain a record of the molybdenum-99 concentration or strontium-82 and strontium-85 concentration tests required by paragraph (B) of rule 3701:1-58-35 of the Administrative Code for three years. The record must include: (A) For each measured elution of technetium-99m, the ratio of the measures expressed as kilobecquerel (microcuries) of molybdenum-99 per megabecquerel (millicurie) of technetium-99m, the time and date of the measurement, and the name of the individual who made the measurement; or (B) For each measured elution of rubidium-82, the ratio of the measures expressed as kilobecquerel (microcuries) of strontium-82 per megabecquerel (millicurie) of rubidium-82, kilobecquerel (microcuries) of strontium-85 per megabecquerel (millicurie) of rubidium-82, the time and date of the measurement, and the name of the individual who made the measurement.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-86 | Records of safety instruction.
Effective:
August 15, 2021
A licensee shall maintain a record of safety
instructions required by rules 3701:1-58-38, 3701:1-58-46 of the Administrative
Code, and the operational and safety instructions required by rule 3701:1-58-58
of the Administrative Code, for three years. The record must include a list of
the topics covered, the date of the instruction, the name(s) of the
attendee(s), and the name(s) of the individual(s) who provided the
instruction.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-87 | Records of surveys after source implant and removal.
Effective:
August 15, 2005
For purposes of this chapter, a licensee shall maintain a record of the surveys required by rules 3701:1-58-44 and 3701:1-58-56 of the Administrative Code for three years. Each record must include the date and results of the survey, the survey instrument used, and the name of the individual who made the survey.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-88 | Records of brachytherapy source accountability.
Effective:
August 15, 2005
(A) A licensee shall maintain a record of brachytherapy source accountability required by rule 3701:1-58-45 of the Administrative Code for three years. (B) For temporary implants, the record must include: (1) The number and activity of sources removed from storage, the time and date they were removed from storage, the name of the individual who removed them from storage, and the location of use; and (2) The number and activity of sources returned to storage, the time and date they were returned to storage, and the name of the individual who returned them to storage. (C) For permanent implants, the record must include: (1) The number and activity of sources removed from storage, the date they were removed from storage, and the name of the individual who removed them from storage; (2) The number and activity of sources not implanted, the date they were returned to storage, and the name of the individual who returned them to storage; and (3) The number and activity of sources permanently implanted in the patient or human research subject.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-89 | Records of calibration measurements of brachytherapy sources.
Effective:
August 15, 2005
(A) A licensee shall maintain a record of the calibrations of brachytherapy sources required by rule 3701:1-58-48 of the Administrative Code for three years after the last use of the source. (B) The record must include: (1) The date of the calibration; (2) The manufacturer's name, model number, and serial number for the source and the instruments used to calibrate the source; (3) The source output or activity; (4) The source positioning accuracy within the applicators; and (5) The name of the individual, the source manufacturer, or the calibration laboratory that performed the calibration.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-90 | Records of decay of strontium-90 sources for ophthalmic treatments.
Effective:
August 15, 2005
(A) A licensee shall maintain a record of the activity of a strontium-90 source required by rule 3701:1-58-49 of the Administrative Code for the life of the source. (B) The record must include: (1) The date and initial activity of the source as determined under rule 3701:1-58-48 of the Administrative Code; and (2) For each decay calculation, the date and the source activity as determined under rule 3701:1-58-49 of the Administrative Code.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-91 | Records of installation, maintenance, adjustment, and repair of remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
August 15, 2005
A licensee shall retain a record of the installation, maintenance, adjustment, and repair of remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units as required by rule 3701:1-58-57 of the Administrative Code for three years. For each installation, maintenance, adjustment and repair, the record must include the date, description of the service, and name(s) of the individual(s) who performed the work.
Last updated November 18, 2022 at 8:41 AM
|
Rule 3701:1-58-92 | Records of safety procedures for remote afterloaders, teletherapy units, or gamma stereotactic radiosurgery units.
Effective:
October 4, 2010
A licensee shall retain a copy of the procedures required by paragraphs (A)(4) and (D)(2) of rule 3701:1-58-58 of the Administrative Code until the licensee no longer possesses the remote afterloader, teletherapy unit, or gamma stereotactic radiosurgery unit.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-93 | Records of dosimetry equipment used with remote afterloader units, teletherapy units, and gamma stereotactic radiosurgery units.
Effective:
August 15, 2005
(A) A licensee shall retain a record of the calibration, intercomparison, and comparisons of its dosimetry equipment done in accordance with rule 3701:1-58-60 of the Administrative Code for the duration of the license. (B) For each calibration, intercomparison, or comparison, the record must include: (1) The date; (2) The manufacturer's name, model numbers and serial numbers of the instruments that were calibrated, intercompared, or compared as required by paragraphs (A) and (B) of rule 3701:1-58-60 of the Administrative Code; (3) The correction factor that was determined from the calibration or comparison or the apparent correction factor that was determined from an intercomparison; and (4) The names of the individuals who performed the calibration, intercomparison, or comparison.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-94 | Records of full calibrations for teletherapy units, remote afterloader units, and gamma stereotactic radiosurgery units.
Effective:
October 4, 2010
(A) A licensee shall maintain a record of the teletherapy unit, remote afterloader unit, and gamma stereotactic radiosurgery unit full calibrations required by rules 3701:1-58-61 to 3701:1-58-63 of the Administrative Code for three years. (B) The record must include: (1) The date of the calibration; (2) The manufacturer's name, model number, and serial number of the teletherapy, remote afterloader, and gamma stereotactic radiosurgery unit(s), the source(s), and the instruments used to calibrate the unit(s); (3) The results and an assessment of the full calibrations; (4) The results of the autoradiograph required for low dose-rate remote afterloader units; and (5) The signature of the authorized medical physicist who performed the full calibration.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-95 | Records of periodic spot-checks for teletherapy units.
Effective:
August 15, 2005
(A) A licensee shall retain a record of each periodic spot-check for teletherapy units required by rule 3701:1-58-64 of the Administrative Code for three years. (B) The record must include: (1) The date of the spot-check; (2) The manufacturer's name, model number, and serial number of the teletherapy unit, source and instrument used to measure the output of the teletherapy unit; (3) An assessment of timer linearity and constancy; (4) The calculated on-off error; (5) A determination of the coincidence of the radiation field and the field indicated by the light beam localizing device; (6) The determined accuracy of each distance measuring and localization device; (7) The difference between the anticipated output and the measured output; (8) Notations indicating the operability of each entrance door electrical interlock, each electrical or mechanical stop, each source exposure indicator light, and the viewing and intercom system and doors; and (9) The name of the individual who performed the periodic spot-check and the signature of the authorized medical physicist who reviewed the record of the spot-check. (C) A licensee shall retain a copy of the procedures required by paragraph (B) of rule 3701:1-58-64 of the Administrative Code until the licensee no longer possesses the teletherapy unit.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-96 | Records of periodic spot-checks for remote afterloader units.
Effective:
August 15, 2005
(A) A licensee shall retain a record of each spot-check for remote afterloader units required by rule 3701:1-58-65 of the Administrative Code for three years. (B) The record must include, as applicable: (1) The date of the spot-check; (2) The manufacturer's name, model number, and serial number for the remote afterloader unit and source; (3) An assessment of timer accuracy; (4) Notations indicating the operability of each entrance door electrical interlock, radiation monitors, source exposure indicator lights, viewing and intercom systems, and clock and decayed source activity in the unit's computer; and (5) The name of the individual who performed the periodic spot-check and the signature of the authorized medical physicist who reviewed the record of the spot-check. (C) A licensee shall retain a copy of the procedures required by paragraph (B) of rule 3701:1-58-65 of the Administrative Code until the licensee no longer possesses the remote afterloader unit.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-97 | Records of periodic spot-checks for gamma stereotactic radiosurgery units.
Effective:
August 15, 2005
(A) A licensee shall retain a record of each spot-check for gamma stereotactic radiosurgery units required by rule 3701:1-58-66 of the Administrative Code for three years. (B) The record must include: (1) The date of the spot-check; (2) The manufacturer's name, model number, and serial number for the gamma stereotactic radiosurgery unit and the instrument used to measure the output of the unit; (3) An assessment of timer linearity and accuracy; (4) The calculated on-off error; (5) A determination of trunnion centricity; (6) The difference between the anticipated output and the measured output; (7) An assessment of source output against computer calculations; (8) Notations indicating the operability of radiation monitors, helmet microswitches, emergency timing circuits, emergency off buttons, electrical interlocks, source exposure indicator lights, viewing and intercom systems, timer termination, treatment table retraction mechanism, and stereotactic frames and localizing devices (trunnions); and (9) The name of the individual who performed the periodic spot-check and the signature of the authorized medical physicist who reviewed the record of the spot-check. (C) A licensee shall retain a copy of the procedures required by paragraph (B) of rule 3701:1-58-66 of the Administrative Code until the licensee no longer possesses the gamma stereotactic radiosurgery unit.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-98 | Records of additional technical requirements for mobile remote afterloader units.
Effective:
August 15, 2005
(A) A licensee shall retain a record of each check for mobile remote afterloader units required by rule 3701:1-58-67 of the Administrative Code for three years. (B) The record must include: (1) The date of the check; (2) The manufacturer's name, model number, and serial number of the remote afterloader unit; (3) Notations accounting for all sources before the licensee departs from a facility; (4) Notations indicating the operability of each entrance door electrical interlock, radiation monitors, source exposure indicator lights, viewing and intercom system, applicators, source transfer tubes, and transfer tube applicator interfaces, and source positioning accuracy; and (5) The signature of the individual who performed the check.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-99 | Records of surveys of therapeutic treatment units.
Effective:
August 15, 2005
(A) A licensee shall maintain a record of radiation surveys of treatment units made in accordance with rule 3701:1-58-68 of the Administrative Code for the duration of use of the unit. (B) The record must include: (1) The date of the measurements; (2) The manufacturer's name, model number and serial number of the treatment unit, source, and instrument used to measure radiation levels; (3) Each dose rate measured around the source while the unit is in the off position and the average of all measurements; and (4) The signature of the individual who performed the test.
Last updated November 18, 2022 at 8:42 AM
|
Rule 3701:1-58-100 | Records of five-year inspection for teletherapy and gamma stereotactic radiosurgery units.
Effective:
August 15, 2021
(A) A licensee shall maintain a record of
the full-inspection servicing for teletherapy and gamma stereotactic
radiosurgery units required by rule 3701:1-58-69 of the Administrative Code for
the duration of use of the unit. (B) The record must contain: (1) The inspector's
radioactive materials license number; (2) The date of
inspection; (3) The
manufacturer's name and model number and the serial number of both the
treatment unit and source; (4) A list of components
inspected and serviced, and the type of service; and (5) The signature of the
inspector.
Last updated November 18, 2022 at 8:43 AM
|
Rule 3701:1-58-101 | Report and notification of a medical event.
(A) A licensee shall report any event as
a medical event, except for an event that results from patient intervention, in
which: (1) The administration of
radioactive material or radiation from radioactive material, except permanent
implant brachytherapy, results in: (a) A dose that differs from the prescribed dose or dose that
would have resulted from the prescribed dosage by more than 0.05 sievert (five
rem) effective dose equivalent, 0.5 sievert (fifty rem) to an organ or tissue,
or 0.5 sievert (fifty rem) shallow dose equivalent to the skin;
and (i) The total dose
delivered differs from the prescribed dose by twenty per cent or
more; (ii) The total dosage
delivered differs from the prescribed dosage by twenty per cent or more or
falls outside the prescribed dosage range; or (iii) The fractionated
dose delivered differs from the prescribed dose for a single fraction, by fifty
per cent or more. (b) A dose that exceeds 0.05 sievert (five rem) effective dose
equivalent, 0.5 sievert (fifty rem) to an organ or tissue, or 0.5 sievert
(fifty rem) shallow dose equivalent to the skin from any of the
following: (i) An administration of
a wrong radioactive drug containing radioactive material or the wrong
radionuclide for a brachytherapy procedure; (ii) An administration of
a radioactive drug containing radioactive material by the wrong route of
administration; (iii) An administration
of a dose or dosage to the wrong individual or human research
subject; (iv) An administration of
a dose or dosage delivered by the wrong mode of treatment; or (v) A leaking sealed
source. (c) A dose to the skin or an organ or tissue other than the
treatment site that exceeds by: (i) 0.5 sievert (fifty
rem) or more the expected dose to that site from the procedure if the
administration had been given in accordance with the written directive prepared
or revised before administration; and (ii) Fifty per cent or
more the expected dose to that site from the procedure if the administration
had been given in accordance with the written directive prepared or revised
before administration. (2) For permanent implant
brachytherapy, the administration of radioactive material or radiation from
radioactive material (excluding sources that were implanted in the correct site
but migrated outside the treatment site) that results in: (a) The total source strength administered differing by twenty
per cent or more from the total source strength documented in the
post-implantation portion of the written directive; (b) The total source strength administered outside of the
treatment site exceeding twenty per cent of the total source strength
documented in the post-implantation portion of the written directive;
or (c) An administration that includes any of the
following: (i) The wrong
radionuclide; (ii) The wrong individual
or human research subject; (iii) Sealed source(s)
implanted directly into a location discontiguous from the treatment site, as
documented in the post-implantation portion of the written directive;
or (iv) A leaking sealed
source resulting in a dose that exceeds 0.5 sievert (fifty rem) to an organ or
tissue. (B) A licensee shall report any event
resulting from intervention of a patient or human research subject in which the
administration of radioactive material or radiation from radioactive material
results or will result in unintended permanent functional damage to an organ or
a physiological system, as determined by a physician. (C) The licensee shall notify by
telephone the Ohio department of health, bureau of environmental health and
radiation protection no later than the next calendar day after discovery of the
medical event. (D) The licensee shall submit a written
report to the Ohio department of health, bureau of environmental health and
radiation protection to the address listed in listed in rule 3701:1-40-04 of
the Administrative Code within fifteen days after discovery of the medical
event. (1) The written report
must include: (a) The licensee's name; (b) The name of the prescribing physician; (c) A brief description of the event; (d) Why the event occurred; (e) The effect, if any, on the individual(s) who received the
administration; (f) What actions, if any, have been taken or are planned to
prevent recurrence; and (g) Certification that the licensee notified the individual (or
the individual's personal representative), and if not, why
not. (2) The report may not
contain the individual's name or any other information that could lead to
identification of the individual. (E) The licensee shall provide
notification of the event to the referring physician and also notify the
individual who is the subject of the medical event no later than twenty- four
hours after its discovery, unless the referring physician personally informs
the licensee either that he or she will inform the individual or that, based on
medical judgment, telling the individual would be harmful to the individual.
The licensee is not required to notify the individual without first consulting
the referring physician. If the referring physician or the affected individual
cannot be reached within twenty-four hours, the licensee shall notify the
individual as soon as possible thereafter. The licensee may not delay any
appropriate medical care for the individual, including any necessary remedial
care as a result of the medical event, because of any delay in notification. To
meet the requirements of this paragraph, the notification of the individual who
is the subject of the medical event may be made instead to that
individual's personal representative. If a verbal notification is made,
the licensee shall inform the individual, or appropriate personal
representative, that a written description of the event can be obtained from
the licensee upon request. The licensee shall provide such a written
description if requested. (F) Aside from the notification
requirement, nothing in this section affects any rights or duties of licensees
and physicians in relation to each other, to individuals affected by the
medical event, or to that individual's personal
representative. (G) A licensee shall: (1) Annotate a copy of
the report provided to the Ohio department of health, bureau of environmental
health and radiation protection with the: (a) Name of the individual who is the subject of the event;
and (b) Identification number or if no other identification number is
available, the social security number of the individual who is the subject of
the event; and (2) Provide a copy of the
annotated report to the referring physician, if other than the licensee, no
later than fifteen days after the discovery of the event.
Last updated May 18, 2023 at 3:27 PM
|
Rule 3701:1-58-102 | Report and notification of a dose to an embryo/fetus or a nursing child.
(A) A licensee shall report any dose to
an embryo/fetus that is greater than fifty millisievert (five rem) dose
equivalent that is a result of an administration of radioactive material or
radiation from radioactive material to a pregnant individual unless the dose to
the embryo/fetus was specifically approved, in advance, by the authorized
user. (B) A licensee shall report any dose to a
nursing child that is a result of an administration of radioactive material to
a breast-feeding individual that: (1) Is greater than fifty
millisievert (five rem) total effective dose equivalent; or (2) Has resulted in
unintended permanent functional damage to an organ or a physiological system of
the child, as determined by a physician. (C) The licensee shall notify by
telephone the Ohio department of health, bureau of radiation protection no
later than the next calendar day after discovery of a dose to the embryo/fetus
or nursing child that requires a report in paragraph (A) or (B) in this
rule. (D) The licensee shall submit a written
report to the appropriate address listed in rule 3701:1-40-04 of the
Administrative Code within fifteen days after discovery of a dose to the
embryo/fetus or nursing child that requires a report in paragraph (A) or (B) in
this rule. (1) The written report
must include: (a) The licensee's name; (b) The name of the prescribing physician; (c) A brief description of the event; (d) Why the event occurred; (e) The effect, if any, on the embryo/fetus or the nursing
child; (f) What actions, if any, have been taken or are planned to
prevent recurrence; and (g) Certification that the licensee notified the pregnant
individual or mother (or the mother's or child's personal
representative), and if not, why not. (2) The report must not
contain the individual's or child's name or any other information
that could lead to identification of the individual or child. (E) The licensee shall provide
notification of the event to the referring physician and also notify the
pregnant individual or mother, both hereafter referred to as the mother, no
later than twenty-four hours after discovery of an event that would require
reporting under paragraph (A) or (B) of this rule, unless the referring
physician personally informs the licensee either that he or she will inform the
mother or that, based on medical judgment, telling the mother would be harmful
to the mother. The licensee is not required to notify the mother without first
consulting with the referring physician. If the referring physician or mother
cannot be reached within twenty-four hours, the licensee shall make the
appropriate notifications as soon as possible thereafter. The licensee may not
delay any appropriate medical care for the embryo/fetus or for the nursing
child, including any necessary remedial care as a result of the event, because
of any delay in notification. To meet the requirements of this paragraph, the
notification may be made to the mother's or child's personal
representative instead of the mother. If a verbal notification is made, the
licensee shall inform the mother, or the mother's or child's personal
representative, that a written description of the event can be obtained from
the licensee upon request. The licensee shall provide such a written
description if requested. (F) A licensee shall: (1) Annotate a copy of
the report provided to the director with the: (a) Name of the pregnant individual or the nursing child who is
the subject of the event; and (b) Identification number or if no other identification number is
available, the social security number of the individual who is the subject of
the event; and (2) Provide a copy of the
annotated report to the referring physician, if other than the licensee, no
later than fifteen days after the discovery of the event.
Last updated May 18, 2023 at 3:27 PM
|
Rule 3701:1-58-103 | Report of a leaking source.
Effective:
October 4, 2010
A licensee shall file a report within five days if a leak test required by rule 3701:1-58-27 of the Administrative Code reveals the presence of one hundred eighty-five becquerels (0.005 microcurie) or more of removable contamination. The report must be filed with the address listed in rule 3701:1-40-04 of the Administrative Code. The written report must include the model number and serial number if assigned, of the leaking source; the radionuclide and its estimated activity; the results of the test; the date of the test; and the action taken.
Last updated November 18, 2022 at 8:43 AM
|
Rule 3701:1-58-104 | Training for the parenteral administration of unsealed radioactive material requiring a written directive.
Effective:
August 15, 2021
(A) Except as provided in rule 3701:1-58-21 of the
Administrative Code, the licensee shall require an authorized user for the
parenteral administration of unsealed radioactive material requiring a written
directive, to be a physician who: (1) Is an authorized user under rule 3701:1-58-40 of the
Administrative Code for uses listed in paragraph (B)(1)(b)(vi)(c) of rule
3701:1-58-40 of the Administrative Code or equivalent United States nuclear
regulatory commission or agreement state requirements; or (2) Is an authorized user under rule 3701:1-58-51 or
3701:1-58-71 of the Administrative code, or equivalent United States nuclear
regulatory commission or agreement state requirements and who meets the
requirements in paragraph (B) of this rule; or (3) Is certified by a medical specialty board whose
certification process has been recognized by the director, the United States
nuclear regulatory commission, or an agreement state under rule 3701:1-58-51 or
3701:1-58-71 of the Administrative Code, and who meets the requirements in
paragraph (B) of this rule. (B) The physician: (1) Has successfully completed eighty hours of classroom
and laboratory training, applicable to parenteral administrations listed in
paragraph (B)(1)(b)(vi)(c) of rule 3701:1-58-40 of the Administrative Code or
equivalent United States nuclear regulatory commission or agreement state
requirements. The training must include: (a) Radiation physics and
instrumentation; (b) Radiation
protection; (c) Mathematics
pertaining to the use and measurement of radioactivity; (d) Chemistry of
radioactive material for medical use; and (e) Radiation biology;
and (2) Has work experience, under the supervision of an
authorized user who meets the requirements in this rule, rule 3701:1-58-21, or
3701:1-58-40 of the Administrative Code, or equivalent United States nuclear
regulatory commission or agreement state requirements, in the parenteral
administrations listed in paragraph (B)(1)(b)(vi)(c) of rule 3701:1-58-40 of
the Administrative Code or equivalent United States nuclear regulatory
commission or agreement state requirements. A supervising authorized user who
meets the requirements in rule 3701:1-58-40 of the Administrative Code, this
rule, or equivalent United States nuclear regulatory commission or agreement
state requirements, must have experience in administering dosages in the same
category or categories as the individual requesting authorized user status. The
work experience must involve: (a) Ordering, receiving,
and unpacking radioactive materials safely, and performing the related
radiation surveys; (b) Performing quality
control procedures on instruments used to determine the activity of dosages,
and performing checks for proper operation of survey meters; (c) Calculating,
measuring, and safely preparing patient or human research subject
dosages; (d) Using administrative
controls to prevent a medical event involving the use of unsealed radioactive
material; (e) Using procedures to
contain spilled radioactive material safely, and using proper decontamination
procedures; and (f) Administering dosages
to patients or human research subjects, that include at least three cases
involving the parenteral administration, as specified in paragraphs
(B)(1)(b)(vi)(c) of rule 3701:1-58-40 of the Administrative Code;
and (3) Has obtained written attestation that the individual
has satisfactorily completed the requirements in paragraphs (B)(1) and (B)(2)
of this rule, and is able to independently fulfill the radiation safety-related
duties as an authorized user for the parenteral administration of unsealed
radioactive material requiring a written directive. The attestation must be
obtained from either: (a) A preceptor
authorized user who meets the requirements in this rule, rule 3701:1-58-21, or
3701:1-58-40 of the Administrative Code, or equivalent United States nuclear
regulatory commission or agreement state requirements, or equivalent agreement
state requirements. A preceptor authorized user who meets the requirements in
this rule, or 3701:1-58-40 of the Administrative Code, or equivalent United
States nuclear regulatory commission or agreement state requirements, must have
experience in administering dosages in the same category or categories as the
individual requesting authorized user status; or (b) A residency program
director who affirms in writing that the attestation represents the consensus
of the residency program faculty where at least one faculty member is an
authorized user who meets the requirements in this rule, rule 3701:1-58-21, or
3701:1-58-40 of the Administrative Code, or equivalent United States nuclear
regulatory commission or agreement state requirements, has experience in
administering dosages in the same dosage category or categories as the
individual requesting authorized user status, and concurs with the attestation
provided by the residency program director. The residency training program must
be approved by the residency review committee of the "Accreditation
Council for Graduate Medical Education," the "Royal College of
Physicians and Surgeons of Canada," or the "Council on Postdoctoral
Training of the American Osteopathic Association," and must include
training and experience specified in paragraphs (B)(1) and (B)(2) of this
rule.
Last updated November 18, 2022 at 8:43 AM
|
Rule 3701:1-58-105 | Report and notification for an eluate exceeding permissible molybdenum-99, strontium-82, and strontium-85 concentrations.
Effective:
August 15, 2021
(A) The licensee shall notify by telephone the department
at 614-644-2727 and the distributor of the generator within seven calendar days
after discovery that an eluate exceeded the permissible concentration listed in
paragraph (A) of rule 3701:1-58-35 of the Administrative Code at the time of
generator elution. The telephone report to the department must include the
manufacturer, model number, and serial number (or lot number) of the generator;
the results of the measurement; the date of the measurement; whether dosages
were administered to patients or human research subjects, when the distributor
was notified, and the action taken. (B) By an appropriate method listed in rule 3701:1-40-04 of
the Administrative Code, the licensee shall submit a written report to the
department within thirty calendar days after discovery of an eluate exceeding
the permissible concentration at the time of generator elution. The written
report must include the action taken by the licensee; the patient dose
assessment; the methodology used to make this dose assessment if the eluate was
administered to patients or human research subjects; and the probable cause and
an assessment of failure in the licensee's equipment, procedures or
training that contributed to the excessive readings if an error occurred in the
licensee's breakthrough determination; and the information in the
telephone report as required by paragraph (A) of this rule.
Last updated November 18, 2022 at 8:43 AM
|
